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1. Introduction 
 The reduction of materials to the nanometric size, in the last decades  has 
been the focus of intense research. Indeed, nanomaterials possess attractive 
properties which can be used, and in some cases are already in use, in many field of 
applications: catalysis, data storage, sensors and biomedicine [1]. In particular, the 
application of nanomaterials in biology and medicine is receiving considerable 
attention, as they hold great promises on improving health care and advancing 
medical research [2].  
Among the others, magnetic nanoparticles (MNPs) with size below 100 nm 
represent one of the most promising class of materials, thanks to their peculiar 
properties.  The first prominent feature which makes magnetic nano-objects 
appealing for biomedical applications is represented by their controllable sizes 
ranging from few nanometres up to tens of nanometres, which are smaller or 
comparable to those of many biological entities, ranging from a single gene (2 nm 
wide and 10-100 nm long) to an entire cell (10-100 µm). The possibility of a 
interaction between such entities at the nanometric scale has progressively attracted 
the attention of many research groups all over the world [2a-b]. Beside their size, 
the importance of MNPs in the field of biomedicine relies on their specific 
properties, the most significant being superparamagnetism [3]. When ferro- or 
ferrimagnetic particles belong to the nanometric size range they become single 
domain, i.e. the formation of magnetic domains is no longer energetically favoured, 
therefore they are characterized by a single magnetic moment given by the sum of 
all the atomic spins comprised in the nanoparticle [4]. This magnetic moment will 
freely fluctuate like in a paramagnet (superparamagnetism) or will be blocked 
along certain favoured crystallographic directions (ferromagnetic-like behaviour) 
depending on whether the thermal energy is larger or smaller than the energy 
barrier separating that directions. This energy barrier is determined by the magnetic 
anisotropy of the material itself and, as a first approximation, is proportional to the 
volume of the MNPs [3].  
 These outstanding properties confer to MNPs unique sensing, moving and 
heating characteristic which can be exploited for bio-analysis or for the early 
diagnosis and therapy of several diseases.  
 It is worthy of noting that for biomedical application, biocompatibility is 
another mandatory requirement, restricting the choice for the inorganic core of the 
MNPs to iron oxides and in particular magnetite or maghemite [5].  
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 At present, most applications of MNPs are based on the following physical 
principles [1a, 2b]:   
 
 the application of controlled magnetic field gradients for remotely direct 
MNPs towards organs or tissues or for moving MNPs tagged biomaterials;  
 the utilization of the magnetic moment of the MNPs to modify the nearby 
proton nuclear resonance (contrast agent (CA) for Magnetic Resonance 
Imaging (MRI)); 
 the excitation of MNPs with an external alternating magnetic field inducing 
an heat release which can be used to selectively destroy tumour cells, 
exploiting their higher sensitivity to a temperature increase than healthy 
tissues (magnetic fluid hyperthermia, MFH).  
 
 For example, MNPs can help in the separation of selected biological 
entities from their native environment, so that concentrated samples may be 
prepared for subsequent analyses or other uses. This process involves two 
steps: 1) the tagging or labelling of the desired biological entity with the 
magnetic material and 2) the separation of these tagged entities via a fluid-
based magnetic separation device. The tagging is possible by coating MNPs 
with suitable functional groups which in turn can provide a selective 
linkage to the target site exposed by a cell or a molecule, and at the same 
time maintain an optimal colloidal stability. A specific binding to the target 
can be achieved by using antibodies or other biological macromolecules 
such as hormones or folic acid [6,2b]. The magnetically labelled material 
can be then separated from its native solution by passing the fluid mixture 
through a region in which a magnetic field gradient is present, so that the 
tagged material is immobilized while the unwanted material is removed, as 
displayed in Figure 1.1. 
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Figure 1.1 : Standard methods for magnetic separation: a) the magnet is attached to the container wall 
of a solution of magnetically tagged (●) and unwanted (○) biomaterials. b) a solution containing tagged 
and unwanted biomaterials flows continuously through a region of strong magnetic field gradient, which 
captures the tagged particles. 
 
 In the field of sensing, MRI, is the area in which MNPs have found their 
major application, since they are capable of enhancing the contrast of the image 
(contrast agents). MRI provides images of the density distribution of protons or 
other nuclei through the application of appropriate magnetic field gradients and 
radiofrequency pulse sequences. MRI exploits the contrast created by different 
nuclear spin-spin (T2) and spin-lattice (T1) relaxation times found in different parts 
of the material to obtain images that can evidence specific differences [7]. This 
technique is widely used in medical clinic to investigate the anatomy and 
physiology of the body. From the obtained images it is possible to evidence local 
pathologies and disease like tumour lesions, edemas, soft tissue damages, muscle 
lesions and many more.  
 Contrast agents are used in order to increase the natural contrast between 
healthy and pathological tissues and they normally act decreasing the relaxation 
times, T1 and T2, of the neighbour protons. At present, the most used CAs are 
based on paramagnetic gadolinium complexes, [8] which increase the contrast by 
magnet 
remove 
supernatant 
fluid flow fluid flow 
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decreasing T1 [8]. However, CAs based on dextran coated assembly of 
superparamagnetic maghemite nanoparticles with a total average diameter between 
20 and 150 nm are also commercially available. In Table 1.1 some examples of 
clinically approved CA for MRI are reported [9]. 
 
Generic Name Metal Trade Name 
Ferumoxides Fe3O4 Endorem®, Fedirez® 
Ferumoxyl Fe3O4 Lumirem®, GastroMARK 
Ferucarbotran Fe3O4 Resovist® 
Ferumoxtran Fe3O4 Sinerem®, Combidex® 
 
Table 1.1 : Clinically approved CA for MRI based on magnetite nanoparticles [9a]. 
 
 Ferrite MNP based CAs perform their function affecting the T2 relaxation 
time of the protons in the nearby tissues, leading to a better contrast in the acquired 
images. The advantages offered by MNPs-based CA, in comparison with 
conventional gadolinium chelates, rely on the enhanced cellular internalization and 
slower clearance from tumour site [10]. In particular, for MNPs with diameters 
greater than 50 nm the cellular internalization is essentially due to the uptake by the 
cells of the reticuloendothelial system (RES), whereas nanoparticles with a 
diameter lower than 50 nm benefit from slower opsonization and RES clearance 
[11]. In all of these cases the tissue distribution of the MNPs relies on a passive 
targeting rather than a direct labelling. Indeed, one of the most challenging 
opportunities is to functionalize the nanoparticles with specific biomolecules 
(monoclonal antibodies, peptides, or other target bioactive molecules) in order to 
direct the CA only to the desired target exploiting a receptor-mediated endocytosis 
and hence increasing a local accumulation in the diseased tissues [12]. This would 
allows both the increase of the sensitivity of the technique and the reduction of the 
amount of contrast agent required to acquire an MRI image.  
 Finally, MNPs can be used as heat mediators in the hyperthermic treatment 
of tumour cells, which is a technique that is progressively acquiring more and more 
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relevance in the fight against tumour pathologies [2a,2b]. Hyperthermia is a general 
term which groups together several techniques, all based on the rise of temperature 
above the physiologic level (in the range of 40-45°C) within a targeted tumour 
without damaging the surrounding healthy tissues [9a]. The most extended method 
for increasing temperature above the systemic values is based on the application of 
microwaves [13], although therapies involving ionizing radiation [14] have also 
been successfully applied to destroy malignant tissues. The disadvantages of these 
strategies are related to undesired collateral effects such as ionization of genetic 
material (radiation) or lack of selectiveness (microwaves) that affect the 
surrounding healthy tissues [15]. Another emerging hyperthermic treatment of 
tumours relies on the application of a radiofrequency on magnetic needles directly 
implanted into the target site [16.]; although very promising, this technique is 
invasive and its effectiveness is rather limited.    
 In this respect inorganic nanoparticles, which, in principle can be localized 
only at the tumour site, can represent a viable alternative. For example, successful 
in vitro and in vivo studies have been reported on the use of functionalized gold 
nanorods to convert infrared radiation (IR) into heat that selectively destroys cancer 
cells [17]. The use of these kind of nanostructures for hyperthermia could be useful 
to avoid damages on healthy cells. On the other hand, IR radiation has a low 
penetration depth into human tissues, which limits this technique to surface 
applications, like melanoma cells [9a]. The employment of MNPs as heat 
mediators for MFH can help to overcome these drawbacks. In this case the 
temperature increasing is realized by means of an external alternating magnetic 
field acting on MNPs at the targeted site, which provides to the particle’s magnetic 
moment the energy required to overcome the barrier generated by the magnetic 
anisotropy. This energy is then released as heat which is dissipated to the 
surrounding tissues. MNPs can be accumulated in tumour tissues thanks to the so 
called enhance permeability and retention (EPR) effect [18]. This mechanism relies 
on leaky vasculature characterizing cancerous tissues, which allows 
macromolecules and nanoparticles to extravasate and accumulate more readily. 
This passive targeting can be exploited to induce a local temperature enhancement 
and, as a consequence to selectively induce tumour cells death. The feasibility of 
MFH has been already demonstrated in clinical trials by the group of Prof. Jordan 
at Berlin’s Charité Hospital, who reported significant benefits in the treatment of 
recurrent glioblastoma multiforme and, more recently of prostate and pancreas 
tumours by using a combination of radiotherapy and heating produced by 12 nm 
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amino-silane coated Fe3O4 MNP directly implanted in the tumour mass at high 
doses (ca. 50 mg/cm
3
) [19]. As it can be inferred from the above description, an 
improvement of the hyperthermic treatment can be accomplished by the use of 
tumour targeted MNPs in order to increase the selectivity and reach the temperature 
enhancement with as low as possible amount of MNPs. Furthermore hyperthermia 
can be used in combination with other cancer therapies like chemotherapy and 
radiotherapy so as to increase their efficacy during the treatment. Moreover, 
chemotherapeutic drugs can be eventually linked to the MNPs used for the 
hyperthermic treatment and released only at the target site [9a, 1a].  
 We have described the appealing properties offered by MNPs that can be 
exploited in the field of biomedicine and, in particular, in the treatment and 
diagnosis of tumour pathologies. However, the most attracting feature is that all the 
above cited functionalities, i.e. sensing, moving and heating, can be combined in a 
unique multifunctional nano-object which ideally can ensure early diagnosis, 
deliver of the treatment to the specific target site at the right dose and time, and 
monitoring of the therapeutic effect. This kind of system will thus work as a 
diagnostic tool and as therapeutic agent, paving the way towards the so-called 
theranostic approach (therapeutic + diagnostic). In Figure 1.2 is provided a 
schematic representation of multifunctional MNPs, consisting essentially of:  
 
 1) a nanometric inorganic magnetic core; 
 2) an organic biocompatible coating; 
 3) a biologically active entity (a protein, an antibody, a small molecule) 
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Figure 1.2 : Theranostic multifunctional MNPs can act simultaneously as diagnostic tools and as 
therapeutic agents.  
 
 Considering this particular aspect we can appreciate the importance that a 
specific functionalization of MNPs could have in the development of an efficient 
tool for theranostic applications. For this purpose it is fundamental to develop a 
specific coating capable to make MNPs biocompatible and highly stable in 
physiological conditions so as to prolong their circulation time and the possibility 
to reach the target-cells [1a].    
 Another fundamental feature offered by MNPs is that they can represent a 
suitable scaffold for the multivalent exposition of biomolecules, which is essential 
for their interaction with biological entities, as indeed required in biomedicine. 
Multivalent interactions are characterized by the simultaneous binding of multiple 
ligands on a biological entity (a molecule or a surface), to multiple receptors on 
another. These interactions are very common in biology and have a number of 
characteristics that monovalent interactions do not possess [20]. Multivalent 
interactions are usually based on not covalent bonds, such as hydrogen bonds, 
metal-ligand coordination, hydrophobic interactions and ionic bonds, which are all 
characterized by low energy and low specificity. However, increasing the number 
of the interactions, they become efficient and specific. Multivalent interactions can 
be collectively much stronger than the corresponding monovalent interactions thus 
providing many advantages. 
Therapy 
Diagnosis 
Antibody Bioactive 
molecule 
Magnetic 
core 
Organic 
coating 
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Figure 1.3 : Ligand - Receptors interactions : monovalent interactions compared to multivalent 
interactions.  
 
  In a multivalent system the intensity of the signal can be simply varied by 
changing the number of ligand-receptors couples involved in the interaction. The 
signal modulation has a crucial role in biology, because the communications 
between biological entities do not rely on a on-off mechanism, and the biological 
answer to any environment alteration must be finely tuned. Moreover, multivalent 
interactions can induce morphological macroscopic modifications in cells during 
communication, thus improving the efficiency of the process. 
 A perfect example of this signal modulation is represented by the role that 
macrophages play in the immune response towards pathogenic organism. Indeed, 
macrophages, are able to engulf and then digest a bacterium only after the 
interaction with two or more antibodies takes place, (Figure 1.4) avoiding an 
immune response in the case of a single antibody bonding.  
 
 
 
Monovalent 
Interactions 
Multivalent 
Interactions 
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Figure 1.4 : Macrophages engulf pathogen organism after an antibodies multivalent interaction. The 
opsonization process marks the bacterium with specific opsonins enhancing phagocytosis. After the 
internalization, the bacteria will be digested in lysosomes (see Chapter 5).    
  
Besides the adhesion of a bacteria to the surface of a cell, multivalent interactions 
are involved in many other biological processes, as for example, the adhesion of 
viruses to host cells, the interaction with toxins or antibodies, or the cell-cell 
communication (Figure 1.5). Some notable practical examples are provided by the 
interaction of influenza virus with bronchial epithelia cells [21] or the lectine-
carbohydrate recognition which is the basis of most of the cell-cell recognition 
processes [22].  
 
 
 
 
Extracellular 
bacteria 
Macrophage 
Opsonization 
Internalization by macrophage 
digestion in lysosome 
Cell 
adhesion 
Cell  
Virus Antibodies 
Bacteria 
Toxins 
Figure 1.5 : Examples of multivalent interactions in biological systems between 
a cell and toxins, bacteria, antibodies, viruses or other cells.  
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 From the scenario described above it clearly emerges that MNPs decorated 
in a multivalent manner with biologically active molecules may hold great 
importance in selective targeting and in the development of novel theranostic tools 
for specific pathologies. In fact the magnetic core of MNPs represents a very 
promising multivalent scaffold. Indeed, if on one hand the multivalent presentation 
of specific epitopes to the immune cells can pave the way towards the application 
in immunotherapy and in particular in the development of antigen-specific vaccines 
[23], on the other the combination with the unique sensing, moving and heating 
properties provided by MNPs, can significantly enlarge the number of diagnostic 
and therapeutic functionalities conjugated in the same nanosystem.  
 As a matter of fact, immunotherapy has emerged as a powerful strategy in 
the fight against tumours and, the development of therapeutic vaccines using 
synthetic antigens, as immunogens, is becoming the ultimate goal in this field. 
Indeed, tumours uniquely or excessively express antigens (Tumour-Associated 
Antigens, TAAs) and, in particular, glycan antigens (Tumour-Associated 
Carbohydrate Antigens, TACAs), which can be useful targets for vaccines. TACAs 
are indeed widely exposed on cancer cell surfaces and their expression often 
correlates with cancer developmental stages, including invasion and metastasis. 
Furthermore, an abnormal glycosylation in the primary tumours is considered a 
signal of poor prognosis [24]. Despite the large numbers of TAAs/TACAs so far 
described, their use in tumour therapy remains limited and needs some 
improvements. This is not only because immune responses in cancer patients can 
be relatively weak, but also because TACAs are poorly immunogenic antigens. 
Moreover, most TACAs are recognized as self and, according to their saccharidic 
nature, they cannot be presented to T cells for T cell responses (T cell independent 
type II antigens). Consequently, the class switch from IgM to IgG and the recall 
memory response are not generated [25]. IgM (immunoglobulin M) is a type of 
antibody produced by B cells, and it is the first antibody elicited in response to 
initial exposure to an antigen; IgG (immunoglobulin G) are also produced by B 
cells but represent the long term response of the body to a disease. IgM are short 
term, disappear after a few weeks and they are then replaced by IgG that provide a 
long lasting immunity [26]. A successful strategy to overcome the limitations 
mentioned above, might be mimicking the natural multivalent approach of the 
molecular biosystems by binding carbohydrate antigens to multivalent scaffolds, 
such as nanomaterials. TACA multivalent display, indeed, mimicking the natural 
multivalent carbohydrate presentation on a cell surface, can lead to B cell 
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activation and antibody production [27]. Furthermore, a nanomaterial, as antigen 
delivery system, can provide an adjuvant activity, inducing the activation and 
maturation of antigen presenting cells (APCs), [28] thus promoting the antigen 
cross-presentation [29]. All these events are essential for the induction of an 
efficient antitumour immune response.  
 In this context, the main target of this thesis has been the synthesis and 
characterization of a novel glycoconjugate nanosystem composed by magnetite 
MNPs functionalized with a synthetic, conformationally rigid mimetic of the α-Tn 
antigen [30], that is a TACA expressed in carcinoma-associated mucins [31], for 
application in immunotherapy. The evaluation of the immunoactivity of the 
glycosylated MNPs was accomplished by means of in vitro tests on the activation 
of macrophages. The choice of macrophages is based on the fact that they represent 
a perfect “bridge” between the innate immunity and the adaptive immunity and 
play a crucial role in the activation and amplification of the immune response [26].    
 In addition, since this work was aimed at the development of a 
multifunctional magnetic nanosystem, important efforts were devoted to the 
development of a suitable synthetic procedure for obtaining MNPs with optimized 
physical and chemical properties for their application in nanomedicine.  
For the synthesis of MNPs we exploited the thermal decomposition of 
metal-organic precursors in high boiling solvent [32]. Several attempts were 
performed in order to obtain highly crystalline, pure magnetite MNPs with a size in 
the 12-15 nm range varying the experimental parameters like the nature of the 
metal-organic precursor, the amount and kind of surfactants, the solvent, or the 
heating ramp. This particular size corresponds to the best compromise between a 
large heating efficiency in magnetic fluid hyperthermia and colloidal stability.     
 Finally, in order to make the proposed approach more versatile, we explored 
diverse functionalization methods, by changing the bifunctional linker used to link 
the saccharidic epitope onto the surface of the MNPs. We thus obtained 
nanosystems with suitable water solubility and suitable to be further coupled with 
bioactive molecules. In particular, we synthesized a new bifunctional linker derived 
from hexaethylene glycol to confer to MNPs the desired solubility and reactivity 
towards further functionalization. 
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For a better comprehension of this PhD work a brief summary is reported here 
after: 
 
 in Chapter 2, the experiments performed for MNPs synthesis, changing the 
precursor for the thermal decomposition and the reaction conditions, in 
order to optimize their structural and physical properties, are described; 
 Chapter 3 is dedicated to the α-Tn antigen mimetic, from its synthesis to the 
bonding to the magnetite MNPs; 
 in Chapter 4 it is described the preparation of functionalized MNPs samples 
used as negative controls for the biological tests on the macrophages 
activation, in order to better evaluate the effect of MNPs decorated with the 
α-Tn antigen mimetic on immune cells; 
 in Chapter 5 the above mentioned biological tests on macrophages 
activation are described in detail; 
 Chapter 6 is focused on the study of bifunctional ligands for MNPs 
functionalization in order to render them suitable for further decoration with 
bioactive molecules. We describe the functionalization of MNPs with an 
aminosilane ligand and then the synthesis of a new bifunctional ligand 
derived from hexaethylene glycol bearing two diverse functional groups: a 
phosphonate group at one end and an amino group at the other; 
 conclusions and future perspective are exposed in Chapter 7; 
 in Chapter 8 all the experimental data and the descriptions of the 
characterization techniques are reported. 
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2. Synthesis of MNPs  
 Nowadays, there is a great interest in the use of MNPs in various field of 
application, from engineering to nanobiotecnology and biomedicine [1]. The 
critical dependence of their physical properties on the particle size, shape and 
structure if on one hand allows for a fine tuning of their behaviour, on the other 
requires a tight control at the synthetic level. As a consequence, a wealth of 
methods of synthesis has been developed to answer to the different need arising 
from the different applications meanwhile granting a fine control on the 
morphological properties. In the literature many procedures are described 
concerning the bottom-up approach and most of them are focused on the thermal 
decomposition of a precursor (metal-organic or inorganic salts) in the presence of 
surfactants in high boiling solvents [2]. It is worth to note that the thermal 
decomposition method is one of the best in terms of crystallinity, size distribution 
and magnetic properties of the final product, particularly if compared with the co-
precipitation method, the sol-gel processes or the synthesis in reverse micelles. 
Thanks to these advantages thermal decomposition has rapidly gained a large 
popularity, becoming one of the most common method for the production of MNPs 
[3]. However, despite of its large popularity, this technique is still suffering some 
drawbacks in terms of reproducibility, phase homogeneity and size or composition 
control. The main hurdle found by each "nanoparticle-chemist" is to reproduce in 
his own laboratory the procedure illustrated in a paper getting the same results. 
This is mainly due to the great number of experimental variables that must be 
simultaneously controlled in the reaction set-up, like the temperature increasing 
rate, the stirring rate, the nitrogen flow and many others. Each one of them affects 
the nature and the quality of the final product, thus it is essential to set all the 
parameters in order to obtain the desired product [4]. 
 In this work the thermal decomposition process has been chosen as the 
principal way to obtain good quality magnetite MNPs exploitable for our purpose. 
In the following paragraph the attempts to synthesize iron oxide MNPs with a 
diameter of about 12-15 nm varying the nature of the precursor and the 
experimental conditions will be described. For each precursor many experiments 
were performed in order to analyze the dependence of the MNPs behaviours on the 
experimental parameters and thus find the best reaction conditions.   
 
2.1 Synthesis with FeOOH 
 The first precursor tested for the thermal decomposition reaction was the 
iron (III) oxide hydrate, FeOOH  in the presence of oleic acid as surfactant and 1-
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octadecene as high boiling solvent (b.p. 320°C). The MNPs were prepared 
following a procedure similar  to that reported by Xue et al [5].  
 
 
 
Precursor Surfactant Solvent 
FeOOH Oleic Acid 1-Octadecene 
 
 
 
  
 
 
 
 
 
 
  
 Different samples were prepared by varying the reaction conditions (Table 
2.1). However the increasing temperature rate and the length of the final step at 
300°C were always kept constant in all syntheses and equal to 10°C/min up to 
180°C and 6°C/min up to 300°C (Figure 2.1). All samples were recovered from the 
reaction mixture by magnetic decantation followed by several 
washing/precipitating steps. Details of the preparation are given in the experimental 
section.  
 
 The reaction was first carried out at a 1:4 precursor/surfactant concentration 
ratio under inert atmosphere. The as prepared MNPs IOMNP1 have an XRD 
pattern compatible with a mixed phase composed by a 53% of the cubic inverse 
spinel structure of magnetite (PDF 89-0691) maghemite (PDF 39-1346) or any 
partially oxidized intermediate ferrite phase, which cannot be discriminated from 
each other by this technique and by a 47% of the rhombohedral structure of 
Sample 
precursor 
surfactant 
Precursor conc. (mg/mL) 
Reaction 
atmosphere 
IOMNP1 1/4 28.5 Inert (N2) 
IOMNP2 1/5.5 7.2 Inert (N2) 
IOMNP3 1/5.5 7.2 Air 
IOMNP4 1/5.5 7.2 bubbling air 
 
      Table 2.1: Experimental conditions used for to thermal decomposition of FeOOH 
Figure 2.1: Heating rate ramp for the thermal decomposition reaction of FeOOH. 
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hematite (PDF 24-0072) (Figure 2.2). The quantification of each phase was 
obtained analyzing the diffraction pattern by the Rietveld method. The same 
procedure was followed for all the phase quantification data reported in this 
chapter.   
30 40 50 60 70
2
(111) (200) (220)
 
Figure 2.2: XRD patterns of samples a) IOMNP1, b) IOMNP2, c) IOMNP3, d) IOMNP4. The black bars 
correspond to the reference magnetite pattern (PDF 89-0691), the red bars correspond to the reference 
hematite pattern (PDF 24-0072), the blue bars correspond to the reference wüstite pattern (PDF 01-
1223).   
 The presence of the hematite phase is undesired since it negatively affects 
the magnetic properties of the final product; indeed, hematite is characterized by a 
transition temperature, known as Morin transition, at TM=263-267 K; below TM 
hematite is purely antiferromagnetic and above TM is weakly ferromagnetic [6]. 
Since for biomedical application we need MNPs with a high magnetic moment, the 
presence of the hematite phase represents a great drawback.  
 In order to obtain the magnetite phase only, the reaction was repeated by 
performing three experiments in a four-fold diluted reaction mixture at a 1:5.5 
precursor/surfactant ratio and varying the atmosphere reaction.   
 Sample IOMNP2 was obtained by accomplishing the reaction under inert 
N2 atmosphere. In this case no evidence of the hematite secondary phase was 
observed in the XRD pattern. However, the pattern reveals the presence of a large 
amount of another parasitic phase: in fact the Rietveld analysis reveals the 
nanopowder is composed by a 63% of magnetite and 37% of wüstite, as it clearly 
appears from the appearance of three peaks, which can be attributed to the (111), 
(a) 
(b) 
(c) 
(d) 
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(200) and (220) families of planes of the cubic face centered structure of wüstite 
over the characteristic pattern of magnetite. The disappearance of the hematite 
(Fe2O3) phase replaced by wüstite (FeO) can be imputed to the higher amount of 
reducing agents, like CO and H2 produced during the thermal decomposition of the 
organic ligand due to the lower precursor/surfactant ratio [7]. Since bulk wüstite is 
paramagnetic at room temperature and presents an antiferromagnetic ordering 
below 200 K, similarly to hematite it reduces the magnetic moment of the MNPs. 
 
 
 
Figure 2.3 : TEM image of sample IOMNP2. In the inset the size distribution evaluated over 550 MNPs 
is reported. The two distributions are centered at 17.9 ± 3.8 nm and 21.0 ± 3.3 nm. 
 Sample IOMNP2 showed the presence of a double population with two 
distributions centered at 17.9 ± 3.8 nm and 21.0 ± 3.3 nm, respectively, as 
highlighted in the inset of Figure 2.3. Despite the sample displayed a good 
homogeneity in terms of shape (almost all the MNPs are spherical), the presence of 
a double population and the large size are not appropriate to our purposes.  
 In order to promote the oxidation of Fe(II) to Fe(III) the reaction was first 
repeated under air atmosphere (sample IOMNP3) and then with air bubbled 
directly into the reaction mixture ( sample IOMNP4). 
 The XRD pattern of sample IOMNP3 still shows the presence of the mixed 
phase magnetite/wüstite but the percentage of magnetite phase increased to 78% 
(the rest 22% being wüstite). The efficacy of a more oxidant atmosphere was 
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demonstrated by the XRD pattern of sample IOMNP4 that displays the complete 
disappearance of wüstite phase, albeit it is possible to find a 17% of hematite 
detectable from the peak assigned to (104) family of planes while the percentage of 
the magnetite phase was found equal to 83%.  
 
 
 
 
Figure 2.4 : Representative TEM image of sample IOMNP3 (d= 9.5 ± 1.7 nm). In the inset the size 
distribution evaluated over 500 MNPs is reported.  
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 Interestingly, sample IOMNP3 retained an almost spherical shape such as 
sample IOMNP2, but the mean size decreased to 9.5 ± 1.7 nm despite the reaction 
atmosphere was the only experimental parameter changed (Figure 2.4). This result 
confirmed the strong dependence of the product's properties on the adopted 
experimental conditions.  
 
 
 
Figure 2.5 : TEM image of sample IOMNP4 (d= 9.4 ± 4.3 nm). In the inset the size distribution evaluated 
over 300 MNPs is reported.  
 In Figure 2.5 a representative TEM image of sample IOMNP4 is shown. In 
this case the shape is very irregular and many large aggregates were formed. The 
inset in Figure 2.5 is a proof of the great polydispersity achieved in this sample (the 
mean size measured was found equal to 9.4 ± 4.3 nm). In conclusion, although the 
"bubbling-air" method has proven useful to avoid the formation of wüstite, it still 
presents some problems: indeed, the flow of air into the reaction mixture interfered 
with the correct increasing temperature rate causing a lowering of the temperature 
up to 250°C, which in turns produced a bad control on MNPs growth. Also the 
stirring rate is negatively affected, worsening the control on the final size and size 
distribution of the MNPs. Moreover, neither the use of bubbling air during the 
reaction led to the formation of a unique crystal phase.  
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2.2 Synthesis with iron(III) oleate  
 Since the results obtained using FeOOH were not satisfactory, an attempt 
was performed by replacing the substrate for the thermal decomposition reaction 
with iron(III) oleate (Fe(ole)3). The use of this precursor is a versatile method 
which allows tuning the mean size of MNPs by simply varying the experimental 
parameters like the heating rate ramp, the Fe(ole)3/oleic acid ratio and the reagents 
concentration. It is worth to note that Fe(ole)3 is not commercially available and 
thus need to be synthesized [8]. In our case we used a well established procedure 
based on the reaction of  FeCl3∙6H2O with  sodium oleate (NaOle) according to the 
scheme below:   
 
 
Scheme 2.1 : Scheme for the synthesis of iron (III) oleate. 
 
 Fe(ole)3 was used in the thermal decomposition reaction in the presence of 
oleic acid as surfactant in a 1:3 precursor/surfactant ratio, using 1-octadecene as 
solvent.  
 
 
 
Figure 2.6: Heating rate ramp for the thermal decomposition reaction of Fe(ole)3. 
 
 The reaction was performed under inert atmosphere (N2) and after 4h of 
reflux the MNPs were recovered by magnetic decantation and purified by several 
washing/precipitating steps (sample OlMNP1). 
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 TEM images (a typical example is shown in Figure 2.7) demonstrate that 
the synthesized MNPs have a spherical shape and a mean diameter of 16.1±1.1 nm 
with a extremely narrow size distribution.  
Figure 2.7 : TEM image of OlMNP1 (d = 16.1± 1.1 nm) . In the inset 
the size distribution evaluated over 550 MNPs is reported.  
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Figure 2.8 : XRD pattern of OlMNP1. The the black bars correspond to the reference magnetite pattern 
(PDF 89-0691), the blue bars correspond to the reference wüstite pattern (PDF 01-1223). 
 However, the XRD pattern of sample OlMNP1, reported in Figure 2.8 
shows, also in this case the presence of two phases, which after the Rietveld 
analysis can be attributed to magnetite (74%) and wüstite (26%). As previously 
stated, wüstite affects negatively the magnetic properties of the MNPs since, due to 
his antiferromagnetic character, it lowers the total magnetic moment of the MNPs. 
In order to eliminate this parasitic product, an attempt of oxidizing wüstite by a 
heating treatment of the MNPs in an oven under air atmosphere at different 
temperatures, (T = 65°C, 90°C, 140°C), and different time (t = 24 h, 48 h at T = 65 
°C) was performed. The obtained results are resumed in Table 2.2, where the phase 
content evaluated from the analysis of the XRD patterns is reported.    
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Figure 2.9 : XRD pattern of sample OlMNP1 before and after the heating treatment. a) as prepared 
MNPs; b) after heating treatment at 65°C for 24h; c) after heating treatment at 65°C for 48h; d) after 
heating treatment at 90°C for 24h; e) after heating treatment at 140°C for 24h. The black bars 
correspond to the reference magnetite pattern (PDF 89-0691), the red bars correspond to the reference 
wüstite pattern (PDF 01-1223)  
 
 Comparing the XRD patterns of sample OlMNP1 before and after the 
heating treatments it is possible to observe a gradual increase of the magnetite 
phase on increasing temperature up to 90°C (Figure 2.9). Indeed, heating the 
sample at that temperature, the wustite content decreases to 7%. Then, a further 
increase in temperature does not produce any significant variation in the relative 
amounts of the two magnetic phases. On the other hand, also increasing the heating 
time does not allow to completely eliminate wüstite (Table 2.2).  
 
 
 
 
 
 
 
(a) 
(b) 
(c) 
(d) 
(e) 
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Heating treatment Magnetite content Wüstite content 
65°C - 24h 85% 15% 
65°C - 48 h 90% 10% 
90°C - 24h 93% 7% 
140°C - 24h 92% 8% 
 
Table 2.2 : Magnetite and wüstite contents in sample OlMNP1 after the heating treatment.. 
 
 Moreover, the average diameter of the sample oxidized at 90°C, evaluated 
by using the Scherrer's formula, was 8.3(2.4) nm pointing out that the temperature 
at which oxidation take place is not large enough to convert the iron oxide into 
crystalline ferrite [9]. It is worth to note that the peak broadening of the XRD 
pattern negatively affected the quality of the fit used for determination of 
crystallites size as well as indicated the low crystallinity of this sample.          
 The magnetic properties of OlMNP1 treated at 90°C, OlMNP1@90, for 
24h were investigated recording the hysteresis loop at 2.5 K and 300 K in the  5 T 
range (Figure 2.10) An open hysteresis loop was measured at 2.5 K with a coercive 
field µ0H of 52 mT and a reduced remnant magnetization M0T/M5T, of 0.30. No 
magnetic irreversibility was observed at 300 K, indicating that the blocking 
temperature, i.e. the temperature at which the nanosystem switches from a blocked 
to a superparamagnetic state is smaller than room temperature. The magnetization 
was almost saturated at the highest measuring field of 5T reaching a value of 53 
Am
2
Kg
-1
 at 2.5 K and then it slightly decreases at room temperature down to 50.5 
Am
2
Kg
-1
. 
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Figure 2.10 : Hysteresis loop recorded at 2.5K (blue dotted line) and at 300 K (red dotted line) and 
corresponding enlargement of the low field region for sample OlMNP1@90. 
 
 The saturation magnetization is lower than the bulk value of 90 Am
2
Kg
-1
 
[10]. This effect can be attributed both to the presence of the antiferromagnetic 
wüstite phase and to the occurrence of surface structure defects that can lead to 
magnetic disorder and hence to a global decrease of the magnetization. 
  In order to obtain MNPs with a higher magnetic moment the oxidation 
procedure was then modified replacing the heating treatment in oven with one in 
solution. To this aim sample OlMNP1 was dissolved in 1-octadecene in the 
presence of oleic acid so as to obtain a stable suspension. A flux of air was then 
bubbled into the reaction mixture which was heated up to T = 290°C at a rate of 
17°C/min. At the end of the oxidation treatment the MNPs were magnetically 
decanted and washed several times in order to remove the excess of surfactant.    
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 The XRD pattern of the as obtained MNPs confirmed the efficacy of the 
oxidation process showing the complete disappearance of the wüstite phase (Figure 
2.12). 
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Figure 2.12 : Comparison between XRD patterns of (a) mixed phase MNPs synthesized from Fe(ole)3,  
(b) OlMNP1@90, oxidized in oven at 90°C for 24h, (c) OlMNP1@290, oxidized in 1-octadecene solution 
at 290°C with bubbling air. 
 
 Moreover, the peak broadening is significantly reduced in this last sample, 
(the average size of the coherent scattering dominion was estimated to be 12.5(0.3) 
indicating the crystal quality was significantly improved by the heating treatment 
carried out in solution. 
Substrate Mixed phase MNPs 
Surfactant Oleic acid 
Solvent 1-octadecene 
Figure 2.11 : Experimental conditions adopted for the oxidation of the mixed phase MNPs. 
(a) 
(b) 
(c) 
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Figure 2.13 : Hysteresis loop of OlMNP1@290, oxidized in 1-octadecene solution at 290°C with bubbling 
air, recorded at 2.5K (blue dotted line) and at 300 K (red dotted line) and corresponding enlargement of 
the low field region. 
 
The hysteresis loop at 2.5 and 300 K of OlMNP1@290 are shown in Figure 2.13. 
An open hysteresis loop was measured at 2.5 K with a coercive field µ0H of 31 mT 
and a reduced remnant magnetization M0T/M5T, of 0.47, while no magnetic 
irreversibility was observed at 300 K. Unlike OlMNP1@90, the magnetization is 
almost saturated at the highest measuring field of 5 T reaching a value of 89 
Am
2
Kg
-1
 at 2.5 K and 83 Am
2
Kg
-1
 at 300 K, very close to value of bulk magnetite, 
confirming the high crystallinity of the MNPs achieved by this method.  
 The hyperthermic properties of both oxidized samples, OlMNP1@90 and 
OlMNP1@290, were investigated recording the temperature kinetic curve of a 
toluene solution when exposed to an alternating magnetic field with amplitude 17 
KAm
-1
 and frequency 183 KHz. The field parameters were set to stay below the 
human tolerance threshold, commonly assumed to be given by H0∙ν < 2 - 5∙10
9
 
A∙m-1∙s-1 [11]. Larger amplitude or frequency may induce deleterious responses of 
living tissues and undesired side effects.  
 The hyperthermic efficiency of a given material is normally evaluate by the 
so-called Specific Absorption Rate, SAR, which is a measure of the absorbed 
power for mass unit [12]. The SAR can be evaluated by calorimetric technique, i.e. 
by measuring the temperature increase ΔT in the interval of time Δt of field 
30 
 
application, using the formula , where, mMe is the total mass of 
metal, mi is the mass of the i-species present in the sample and Cpi its specific heat. 
Since the measurements are carried out in non adiabatic conditions, the ΔT / Δt 
values were extrapolated from the initial slope (t→ 0) of the temperature kinetic 
curves. Moreover, the time elapse Δt is chosen much shorter than the time constant 
of the external thermalization circuit.  
 The SAR values found for  OlMNP1@90 and OlMNP1@290 were 4 Wg
-1
 
and 24 Wg
-1
, respectively (Figure 2.14). The difference in the heat dissipation 
efficacy among the two samples is a further confirmation that the oxidation process 
carried out at low temperature led to poor crystallinity, low magnetic moment and 
hence to bad hyperthermic properties. 
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Figure 2.14 : Temperature kinetics of  MNPs colloidal solutions in toluene : OlMNP1@90 (red, 1.2 % 
w/w) and OlMNP1@290 (black, 0.9 % w/w) during the exposure to the alternating magnetic field (17.0 
kA/m, 183 kHz). 
 
 
 
 
t
T
m
cm
SAR
Me
i
pii



31 
 
2.3 Synthesis of magnetite MNPs with Iron Acetylacetonate 
  
 As we have previously seen, the thermal decomposition of Fe(ole)3 
followed by an oxidation step can provide a final product with suitable structural an 
physical properties. However, despite of this positive aspect, this method still had 
some drawbacks that may affect its reproducibility. For instance, it has been 
recently shown that the properties of the final MNPs are dependent upon aging of 
the precursor [13]. Moreover, the use of a two steps process may be critical for the 
reproducibility. Therefore, we explored a third approach which uses iron(III) 
acetylacetonate as a precursor.   
 Iron(III) acetylacetonate (Fe(acac)3) is a widely used precursor for the 
synthesis of magnetite MNPs [14]. However, a major drawback is represented by 
the difficulties in  obtaining MNPs with size larger than 8-9 nm, in a single reaction 
step. However, it is known from the literature that, in order to have a sizable 
heating at magnetic field tolerable by human being, iron oxide MNPs must be at 
least larger than 10 nm [15]. In order to overcome this limitation we first attempted 
to increase the average size using the so-called seed mediated growth approach. 
This method consists in preparing small MNPs to be used as seeds to grow larger 
MNPs in a following thermal decomposition reaction with a further addiction of  
Fe(acac)3 [16]. 
 As an alternative approach, we explored the modification of experimental 
parameters from the solvent to the heating rate ramp, to increase the average size 
without compromising neither the crystalline quality, nor the magnetic properties.    
 
 
2.3.1 Synthesis of MNPs exploiting the seed mediated growth process 
  
 The synthesis of magnetite MNPs exploiting the seed mediated approach 
starting from Fe(acac)3 as precursor was performed as follows: first nearly cubic 
iron oxide MNPs, IAMNP1, with an average size of 7.6 ± 0.7 (Figure 2.15) nm 
were synthesized by thermal decomposition of Fe(acac)3 in 1-octadecene and with 
oleic acid and oleylamine as surfactants.  
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Figure 2.15 : TEM image of IAMNP1 (d = 7.6 ± 0.7 nm) used for the seed mediated growth process. In 
the inset, the size distribution evaluated over 300 MNPs is reported.  
 Then, the size of the inorganic core was increased by reacting the former 
MNPs with more Fe(acac)3 under the same experimental conditions. TEM images 
of the final product IAMNP2 show that an almost cubic shape was retained while 
the average size calculated along the diagonal increased to 11.3 ± 1.3 nm (Figure 
2.16).    
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Figure 2.16 : image of IAMNP2 (d = 11.3 ± 1.2 nm) after the seed mediated growth process. In the inset 
the size distribution evaluated over 600 MNPs is reported.  
 The position and the relative intensity of all peaks observed in the powder 
XRD pattern (Figure 2.17) well match those of the fcc spinel structure of standard 
magnetite (PDF 19-0629), However, the lattice parameter, a, is 8.382(5) Å, much 
closer to that of magnetite (8.396 Å) than to maghemite (8.346 Å). Notably, no 
evidence of the presence of wüstite was found in the XRD pattern. The average 
diameter, evaluated by using the Scherrer’s formula, was 11.5±0.8 in a good 
agreement with the particle sizes observed in TEM images, pointing out the single 
crystal nature and the high crystallinity of the MNPs. 
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Figure 2.17 : Powder X-Ray Diffraction patterns of MNPs (a) IAMNP1, before  and (b) IAMNP2, after 
the seed-mediated growth step. The black bars correspond to the reference magnetite pattern (PDF 19-
0629). 
 
 The magnetic properties of a colloidal solution of the MNPs in heptane 
were investigated both as a function of temperature and magnetic field. Since these 
MNPs were used as multivalent scaffold for the functionalization with the α-Tn 
antigen mimetic, as it will be described in detail Chapter 3, their magnetic 
behaviours were deeply investigated. The temperature dependence of the 
magnetization recorded after zero-field cooling (ZFC) and field-cooling (FC) 
procedures is reported in Figure 2.18a. It displays the thermal irreversibility 
characteristic of an ensemble of randomly oriented single domain MNPs [17]:
 
at 
room temperature all the particles are in the superparamagnetic regime, 
consistently with the relatively small size of the MNPs, while below ca. 100 K the 
two magnetization curves split, indicating the beginning of the freezing process of 
the MNPs magnetic moment. The blocking temperature, which at first 
approximation can be identified with the temperature of the maximum of the ZFC 
curve, was 50 K, which well agrees with that expected for magnetite MNPs of 11-
12 nm [18]. Accordingly, an open hysteresis loop with a coercive field, HC, of 34 
mT, and reduced remnant magnetization, M0T/M5T, equal to 0.49 was measured at 
low temperature (2.5 K), while no magnetic irreversibility appears when the loop 
(a) 
(b) 
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was measured above the blocking temperature (at 150 K and at room temperature, 
Figure 2.18b). 
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 The magnetization was almost saturated at the highest measuring field of 5 
T (the difference between the values measured at 5 T and those extrapolated from 
the fit of the high field data point to the empirical law M = MS+a/H +b/H
2
 is ca. 1 
%) reaching 75 Am
2
/kg at 2.5 K and then slightly decreasing on increasing 
temperature. The saturation magnetization resulted close to the literature value of 
the corresponding bulk materials confirming the single crystal nature and the high 
cristallinity of the inorganic cores.  
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Figure 2.18 : (a) Temperature dependence of the ZFC and FC magnetizations collected on a colloidal 
solution of the surfactant coated MNPs in heptane with a probe field of 5 mT. (b) Hysteresis loops 
recorded at 2.5 K (red), 150 K (black) and 300 K (blue curve) and corresponding enlargement of the 
low field region (inset). 
Figure 2.19 : AC susceptibilities and Arrhenius plot. (a) Temperature dependence of in-phase, χ’, 
(full symbols) and out-of-phase, χ", (open symbols) AC susceptibilities. Data were collected at 6 log-
spaced frequencies in the 1-1000 Hz range. (b) Arrhenius plot of the experimental relaxation time 
and  best fit line. 
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 The relaxation dynamics of the magnetic moment was further investigated 
by temperature-dependent AC susceptibility measurements at variable frequency 
(1-1000 Hz, Figure 2.19). Both the in- and out-of-phase components of the 
magnetic susceptibility exhibited frequency-dependent maxima characteristic of a 
blocking process. The blocking temperatures obtained from the maxima of the out-
of-phase component of the magnetic susceptibility, χ”, for different observation 
times τ = 1/2πν, where ν is the frequency of the ac field, can be effectively fitted to 
an Arrhenius law,  = τ0 exp(KV/kBT), where K is the magnetic anisotropy energy 
density, V is the particle volume, τ0 the attempt time and  kB the Boltzmann 
constant. The best-fit parameters found were 3∙10-13 ± 2∙10-13s for the pre-
exponential factor, τ0, and 863 ± 18 K for the reversal energy barrier, KV/kB, which, 
considering the average volume obtained from the analysis of TEM images, 
corresponds to K ≈ 2.2·104 J/m3. Interestingly, no anomalies in the χ' vs. T curves 
were observed nor at the melting point of heptane (183 K), or at higher 
temperature, a result which indicates that at room temperature, at least in the 
investigated time window, the reversal of the magnetization is mainly driven by the 
Néel mechanism, rather than by the mechanical rotation of the whole MNPs. This 
result is particularly important in view of the possible application of these 
nanosystems in clinics. Indeed, since in our case the relaxation is determined by 
intrinsic magnetic parameters rather than on extrinsic parameters, as it would have 
been if the relaxation were dominated by Brownian motion of the nanoparticle, we 
can reasonably assume the observed behaviour will not change once the particles 
will be introduced in human tissue.     
 In order to evaluate the heat dissipation efficiency we recorded the 
temperature kinetic curve of the heptane colloidal solution when exposed to an 
alternating magnetic field with amplitude H0 = 11.0 kA/m and frequency ν = 183 
kHz. Also in this case, the field parameters were set to stay below the human 
tolerance threshold, commonly assumed to be given by H0∙ν < 2 - 5∙10
9
 A∙m-1∙s-1 
[11]. The application of this alternating field on a 1.9 % w/w solution of the MNPs 
for 5 minutes produced a sizable temperature increase of ca. 9°C corresponding to 
a SAR value of ca. 10 W/g, as shown in Figure 2.20. Although this value is low if 
compared to data reported in the literature (which are however, commonly obtained 
using much higher, clinically unexploitable field amplitudes) it corresponds to a 
sizable heating efficiency, which suggests this material can be possibly used as heat 
mediator in adjuvant antitumoral therapy.  
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Figure 2.20 : Temperature kinetics of a colloidal solution of iron oxide MNPs during the exposure to the 
alternating magnetic field (11.0 kA/m, 183 kHz). 
 The low SAR value can be attributed both to the small size of the MNPs 
(which, for magnetite is close to the lower limit for producing sizable heat 
dissipation at these field parameters) and the presence of strained lattice regions 
that can alter the magnetic structure of the crystals creating a discrepancy between 
the crystal size and the effective magnetic volume. Pellegrino et al. had 
demonstrated that the origin of this crystal strain is strictly correlated with the seed 
mediated growth method [19]. This particular drawback turned our efforts toward 
the development of a procedure to synthesize larger magnetite MNPs in a single 
reaction avoiding any seeded process.       
 
 
2.3.2 Synthesis of larger magnetite MNPs from iron(III) acetylacetonate 
  
 As mentioned in the previous paragraph, the synthesis of magnetite MNPs 
with size above 10 nm without exploiting the seed mediated growth process is 
often challenging and hard to achieve. Nevertheless, due to the intrinsic limitation 
of the seed growth method, we decide to make an effort to verify if by changing 
various experimental parameters in the thermal decomposition of Fe(acac)3, 
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ranging from the composition of the reaction mixture to the heating rate ramp, were 
possible to get magnetite MNPs with average size above 10 nm.  
 To realize this goal we maintained oleic acid and oleylamine as surfactants 
but changed the precursor/surfactant ratio and the reagents concentration. Both 
parameters are important in the nucleation and growing phase [20]. Differently 
from the previously described synthesis, in this case the employment of 1,2-
hexadecanediol was avoided because, as demonstrated by Barron et al., it promotes 
the formation of small sized MNPs, meanwhile not providing any advantage in 
terms of polydispersity index [21]. Moreover, the reaction solvent was changed 
from 1-octadecene (b.p. 320°C) to benzyl ether (b.p. 298°C) thus facilitating the 
MNPs purification from the reaction mixture. The removal of octadecene residues 
is indeed more difficult causing a larger consumption of hexane and ethanol for the 
purification process.    
 The first two experiments were performed with a Fe(acac)3/oleic 
acid/oleylamine ratio equal to 1 : 4.5 : 3.5 in 50 mL of benzylether, varying ti (the 
time spent to reach reflux condition) and tr (reflux time) in the heating rate ramp as 
described in Figure 2.21. 
 
               
 
Figure 2.21: Heating ramp employed for the synthesis of samples IAMNP3 and IAMNP4 where ti 
represents the time spent to reach reflux condition and tr the reflux time. 
 
 
 The XRD patterns of both samples, shown in Figure 2.22, well match that 
of the fcc spinel structure of magnetite (PDF 88-0315) and no traces of any other 
crystal phase appears confirming that the use of Fe(acac)3 as precursor avoid the 
formation of any undesired phase like wüstite or hematite.  
IAMNP3 : ti=50' and tr=50' 
IAMNP4 : ti=20' and tr=40' 
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Figure 2.22 : XRD patterns of samples IAMNP3 and IAMNP4. In red the reference pattern of magnetite 
(PDF 88-0315) is shown.  
 
 From the TEM images shown in Figure 2.23 it is possible to observe that 
sample IAMNP3 was mostly composed by faceted polyhedral nanocrystals with an 
average size of 20.7 ± 2.6 nm whereas MNPs in sample IAMNP4 had an almost 
spherical shape with a mean size of 7.3 ± 2.0 nm: the transition from the spherical 
to a faceted polyhedral morphology is usually found in MNPs bigger than 15-16 
nm. In the case of sample IAMNP3 the longest ti and tr times favored the growth 
step with respect to nucleation, thus leading to the formation of MNPs bigger than 
20 nm, grown along the most favorable crystallographic directions. Conversely, the 
shortening of ti in sample IAMNP4, smaller MNPs were achieved. In both cases 
the large size distribution can be attributed to the inadequate separation between the 
nucleation and the growing phases.     
 
 
IAMNP3 
IAMNP4 
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 Therefore, an intermediate, 20 minutes long, step at 200°C was added in 
order to improve the monodispersity of the MNPs [22]. The separation between  
nucleation and growth phases, which occur at different temperatures, is a critical 
issue for the formation of nanocrystals of the desired size. Three experiments were 
performed maintaining the same Fe(acac)3/oleic acid/oleylamine ratio equal to 1 : 
4.5 : 3.5 in a two-fold more diluted reaction mixture in comparison to the previous 
experiments. The time tr at which each reaction was maintained at the reflux 
temperature was increased from 15' to 1.5 h as described in Figure 2.24. 
   
       
 
Figure 2.24 : Heating rating ramp employed for the synthesis of samples IAMNP5, IAMNP6 and  
IAMNP7. tr represents the reflux time. 
    
Figure 2.23 : TEM images ad size distribution of samples a) IAMNP3 (d=20.7 ± 
2.6 nm) and b) IAMNP4 (7.3 ± 2.0 nm). The size distribution was evaluated over 
300 MNPs.  
IAMNP5 : tr=15' 
IAMNP6 : tr=40' 
IAMNP7 : tr=1.5 h 
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 The three XRD patterns of the as synthesized samples well match the 
reference pattern of magnetite (PDF 88-0315) as shown in Figure 2.25.  
30 40 50 60 70
2
 
Figure 2.25 : XRD patterns of samples IAMNP5, IAMNP6 and IAMNP7. In red the reference pattern of 
magnetite (PDF 88-0315). 
 
 The average diameters, evaluated by using the Scherrer’s formula for 
samples IAMNP5, IAMNP6 and  IAMNP7 were respectively 10.8±0.2 nm 
13.8±0.2 nm, and 14.5±0.2 nm, in a good agreement with the particle sizes 
observed in TEM images, pointing out the single crystal nature and the high 
crystallinity of the MNPs. 
  
 In Figure 2.26 are shown the TEM images of the three samples and their 
size distributions. 
 
     
IAMNP7 
IAMNP6 
IAMNP5 
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Figure 2.26 : TEM images and size distributions of samples a) IAMNP5 (d = 12.4 ± 1.6 nm) b) IAMNP6 
(d = 15.7 ± 1.7 nm) and c) IAMNP7 (d = 15.6 ± 1.9 nm) . The size distribution was evaluated over more 
than 300 MNPs for samples a and b, and over 500 MNPs for sample c. 
 The size increase was achieved increasing the tr from 15' to 40' going from 
12.4 ± 1.6 nm for sample IAMNP5 to 15.7 ± 1.7 nm for sample IAMNP6. A 
further increase of tr to 1.5h did not affect the size of the synthesized MNPs. A 
better size distribution was obtained for these samples in comparison to carrying on 
the reaction set up without the intermediate step at 200°C. Moreover, a heating 
ramp divided in two steps allowed for a better control on MNPs size and size 
distributions. 
 Based on these last results, the reaction was modified by the introduction of 
a longer heating step at 200°C in order to promote only the formation of nuclei  and 
better separating it from the growth step which occurs in the following step at a 
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higher temperature. In this way the final size is determined by the length of the 
reflux time only.  
 The intermediate step was thus extended to one hour and  tr was equal to 
30'. The other experimental parameters were kept unaltered.   
 
 
 
 
Figure 2.27 : Heating rate ramp used for the synthesis of sample IAMNP9.  
  
 The MNPs IAMNP9 obtained using this heating ramp were structurally 
characterized by x-ray diffraction spectroscopy and transmission electron 
microscopy. Also in this case the XRD pattern, displayed in Figure 2.28, well 
match those of the fcc spinel structure of magnetite (standard: PDF 88-0315) and 
no traces of wüstite or hematite were found.  
30 40 50 60 70
2
 
Figure 2.28 : Pattern of sample IAMNP9. The red lines corresponds to the magnetite reference (PDF 88-
0315). 
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 The TEM images showed uniform MNPs with an average diameter of 13.9 
± 1.0 nm and a highly narrow size distribution. All the MPs had a regular, almost 
spherical, faceted shape, which suggested a slow growth of the nanocrystals and a 
high crystallinity (Figure 2.29). Indeed, the Scherrer analysis of peak broadening of 
XRD pattern revealed an average crystal size of 10.9(0.2) nm. 
 
Figure 2.29 : TEM image of IAMNP9 (d = 13.9 ± 1.0 nm). In the inset the size distribution evaluated over 
700 MNPs is reported. 
  
In this case the good size distribution can be attributed to the adequate length of the 
intermediate step employed, which guarantee the separation between the nucleation 
and the growth phases. Moreover, using a reflux time of 30' allowed to stop the 
growth of the MNPs at the optimal size of ca. 14 nm, before they could become 
bigger and thus less soluble because of the increased  interparticle dipolar 
interaction.  
 In Figure 2.30 the hysteresis loop recorded between 5 T are shown. An 
open hysteresis loop was measured at 2.5K with a coercive field HC of 24 mT, and 
a reduced remnant magnetization, M0T/M5T, equal to 0.37. No magnetic 
irreversibility was observed in the hysteresis loop measured at 300K. The 
magnetization was saturated from 2 T and reached 88 Am
2
/kg at 2.5 K, close to the 
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corresponding value of the bulk material. These magnetic behaviours confirmed the 
single crystal nature and the high crystallinity of the as prepared magnetite MNPs.  
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Figure 2.30: Hysteresis loop of MNPs IAMNP9 recorded at 2.5K (blue dotted line) and at 300 K (red 
dotted line) and corresponding enlargement of the low field region.  
 
 In order to have a complete characterization of this sample, the heat 
dissipation efficiency under an alternating magnetic field with an amplitude of 17 
KAm
-1
 and a frequency of 183 KHz was measured giving a SAR value of 16 W/g, 
a good result if the relatively small size of the MNPs (14 nm) is taken into account 
(Figure 2.31).  
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Figure 2.31 : Temperature kinetics of IAMNP9 colloidal solutions in toluene (1.2% w/w) during the 
exposure to the alternating magnetic field (17.0 kA/m, 183 kHz). 
 
 We can thus conclude that the last experimental conditions correspond to 
the best suited setting to obtain magnetite MNPs to be used for the application 
proposed in this work. As a matter of fact, this particular size represents the best 
compromise between magnetic/hyperthermic properties and colloidal stability. 
Indeed, it has been shown that for fixed field parameters, the specific loss power is 
strongly size-dependent and it reaches a maximum for a size that, for magnetite 
MNPs is ca. 18 nm . However, the stability of magnetite MNPs with size over 15-
16 nm is low affecting the following ligand exchange reactions. 
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3. The α-Tn antigen mimetic and functionalization of MNPs 
 As previously mentioned in Chapter 1, one of the main goal of this work 
was to realize a nanostructured system for the multivalent presentation of the 
TACA α-Tn antigen [1] exploiting a versatile scaffold represented by MNPs. In 
paragraph 3.1, the nature and role of α-Tn antigen is discussed, whereas in the 
following paragraphs 3.2, 3.3, 3.4 we describe the synthesis of the α-Tn antigen 
mimetic modified so as to be anchored to the MNPs surface, and in paragraph 3.5, 
details concerning the functionalization of MNPs with the mimetic are reported.     
3.1  The α-Tn antigen 
 Tumours uniquely or excessively express antigens (tumour associated 
antigens, TAAs) and, in particular, glycan antigens (tumour associated 
carbohydrate antigens, TACAs), which can be exploited as targets for vaccines. 
Among the large numbers of TACAs we focused our efforts on the study of the α-
Tn antigen which is expressed in carcinoma associated mucins [2]. Structurally the 
α-Tn antigen is a N-acetylgalactoseamine (GalNAc) bound through an α-O-
glycosidic linkage to a serine (Ser) or a threonine (Thr) residue (Figure 3.1) of the 
protein backbone of a particular family of glycoprotein, called mucins. Mucins are 
heavily O-glycosilated extracellular proteins forming a major part of the protective 
biofilm on epithelial cells and providing a protective barrier against dangerous 
chemicals or microbials [3].        
 
Figure 3.1 : Structure of the α-Tn antigen. 
 Mucins play several physiological roles acting as a "lubricant" towards the 
internal organs thanks to their density and viscosity: Moreover, they can play the 
role of receptor/sensor transmitting signals in response to external stimuli and 
inducing a proper cellular reaction. However, a mucin over expression matches the 
pathogenesis of cancer, particularly of adenocarcinomas, and harmfully influences 
cellular growth, adhesion, and also the immune surveillance [3]. Mucins, when 
abnormally over expressed, can undergo an incomplete glycosylation leading to an 
exposure of tumour associated epitopes on the surface of the tumour cells. The α-
Tn antigen is one of the truncated forms of the O-glycan chains expressed on 
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cancer cells as displayed in Figure 3.2, and this is why it is considered a promising 
target for cancer  immunotherapy. Noteworthy the α-Tn antigen due to its structural 
simplicity has been a privileged synthetic target for vaccine development [2]. 
   
 
 
 
 
Figure 3.2 : Mucins are heavily glycosylated proteins but during carcinogenesis incomplete glycosylation 
occurs resulting in TACAs exposure. Certain types of cancer cells express truncated forms of O-glycan 
chains and one of them is the α-Tn antigen. 
a) Mucins in healthy cells 
b) Mucins in cancer cells 
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 Our efforts in this field have been directed towards the binding of a stable 
mimetic of the α-Tn antigen 2 (Figure 3.3) to multivalent scaffolds mimicking the 
natural multivalent approach of the biosystems in order to induce an efficient 
antitumour immune response. The development of bioactive mimetics relies on the 
fact that a variety of vaccines based on native TACAs, such as α-Tn, have shown 
low immunogenicity, low in vivo stability and poor bioavailability, giving rise to 
the necessity of improving their stability against chemical and enzymatic 
hydrolysis, as well as of their bioavailability compared to natural materials. 
 
3.2  Synthesis of the α-Tn antigen mimetic 2 
 As described in the previous paragraph the native form of the α-Tn antigen 
1 consists of a N-acetyl galactosamine α-O-linked to a serine (Ser) or a threonine 
(Thr) residue to the peptide backbone. The main challenge of any synthetic 
approach reported for the α-Tn antigen was represented by the stereoselective 
formation of the α-O-glycosidic linkage between the GalNAc and Ser/Thr 
derivatives [4]. 
 
 
 
Figure 3.3 : Structures of the α-Tn antigen 1 and the α-Tn antigen mimetic 2. 
 
 The research group of Prof. C. Nativi has recently developed a 
diastereoselective synthesis of a rigid mimetic of the α-Tn antigen, 2, (Figure 3.3) 
relying on the efficient inverse electron-demand Diels-Alder reaction between the 
glycals and the α-α'-dioxothiones, as outlined in Scheme 3.1 [5]. This mimetic 
maintains the key structural features of the natural α-O-glycopeptide and presents a 
suitable carboxylic functional group for the insertion of a desired linker or carrier 
[6]. Furthermore, the structurally rigid compound 2 preserves the 
4
C1 conformation 
and it is recognized by viscumin album agglutinin (VAA), a lectin which 
selectively binds galactose residues and competes with lactose, a common ligand 
1 2 
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for VAA known to enter the lectin sites, in competitive STD experiments [6]. 
Moreover, it has been recently demonstrated that the mimetic 2 if properly 
functionalized, was able to  induce a strong and long-lasting Tn-specific response, 
with IgM/IgG antibodies able to recognize native carbohydrate antigens, 
confirming its importance in the development of anticancer vaccines  [7]. 
 
 
 
 
Scheme 3.1 : Inverse electron-demand Diels-Alder reaction between glycals and α-α'-dioxothiones 
leading to the diastereoselective formation of the α-O-glycosides. 
 
 The strategy adopted to decorate the MNPs in a multivalent manner with 
the α-Tn like epitope 2, is based on the synthesis of compound 3 starting from the 
peracetylated Tn-like derivative 4. Then in order to exploit the large affinity of 
phosphonate group [8] for the iron oxide surface of the MNPs, compound 3 was 
coupled with the hexaethylene glycol derived linker 5, whose terminal amino group 
was later replaced by a phosphonate moiety, as outlined in the Scheme 3.2. 
 
 
 
 
 
Scheme 3.2 : General scheme for the synthesis of the α-Tn like derivative 3 from the peracetylated Tn-
like derivative 4 and the linker 5.  
 
 
4 3 
Glycal 
(electron rich dienophile) 
α-α'-dioxothione 
(electron poor diene) 
5 
cycloadduct 
phosphonate 
insertion 
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 In this paragraph the synthesis of compound 4 will be described, whereas 
the synthesis of compounds 5 and 3 will be described in paragraphs 3.3 and 3.4, 
respectively. 
 In Scheme 3.3 the complete synthesis of the peracetylated α-Tn antigen 
mimetic 4 is reported. 
      
 
 
Scheme 3.3 : Complete reaction scheme for the synthesis of the peracetylated α-Tn antigen mimetic 4. 
 The D-galactal 6 was reacted with di-tert-butylsylyltriflate ((tBu)2Si(OTf)2) 
affording compound 7 in 90% yield. In this step the hydroxyl groups in positions 
four and six were simultaneously protected as silyl ether. The hydroxyl in position 
three was kept unprotected in order to avoid an increase in steric hindrance on the α 
face of the dienophile that could negatively affect the selectivity in the subsequent 
cycloaddiction reaction.    
4 
6 7 
16 
8 
17 
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 The inverse electron-demand Diels Alder reaction that afforded the 
cycloadduct 8 needs to be discussed in detail. The protected D-galactal 6 
represented the electron rich dienophile whereas the electron poor diene 9 was 
generated in situ from its precursor, the β-ketoester, 10, under the same reaction 
conditions of the cycloaddiction reaction. Indeed, the α-α'-dioxothione 9 is unstable 
and hence impossible to isolate. Compound 10 was prepared exploiting the reaction 
of aspartic acid, 11, bearing the amine group protected with the tert-
butyloxycarbonyl group (Boc) and the carboxylic group protected as benzyl ester 
with the Meldrum acid 12 in the presence of isopropylchloroformiate (IPCF) to 
form the corresponding adduct 13. Then by heating 13 in a 4:1 mixture of 
benzene/methanol, the β-ketoester 10 was obtained (Scheme 3.4) [5]. 
 
 
  
 
 
Scheme 3.4 : Synthesis of the β-ketoester 10, precursor of the α-α'-dioxothione 9 acting as electron rich 
dienophile in the inverse electron-demand Diels Alder reaction. 
 
 The formation of the α-α'-dioxothione 9 was thus achieved by reaction of 10 
with phthalimidesulfenyl chloride (PhtNSCl) 14 [5] in basic conditions in the 
presence of the dienophile, that is the experimental condition of the cycloaddiction 
reaction,  as described in the following scheme 3.5: 
 
11 
10 
13 12 
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Scheme 3.5 : In situ formation of the α-α'-dioxothione 9 in the presence of phtalimidesulfenyl chloride 14 
under basic conditions. 
 
 Phthalimidesulfenyl chloride 14 was prepared by heating N-N'-
dithiobisphtalimide 15 with sulfurilchloride. 
 
 
Scheme 3.6 : Preparation of the phtalimidesulfenyl chloride 14. 
 The Diels Alder reaction between the dienophile 7 and the diene 9 
generated in situ afforded the pure diasteromeric cycloadduct 8 in 52% yield 
(Scheme 3.6). This cycloaddition is characterized by: 
 chemoselectivity: the α-α'-dioxothione reacts selectively with the C=S and 
the ketonic C=O; 
 regioselectivity: the preferred orbital interactions are those between the C=S 
and the galactal C-2 and those between the ketonic C=O and the C-1; 
 stereoselectivity: the interaction occurs involving the lower face of the 
dienophile (α face).  
 
 
Figure 3.4 : Representation of the regio, chemo and stereo selectivity of the inverse electron-demand 
Diels Alder reaction. 
9 10 
15 14 
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 All these features led to the formation of the oxathiin ring presenting the α-
O-glycosidic linkage and a proper orientation of the amino acid moiety with respect 
to the galactosidic counterpart, which are the main characteristics for the α-Tn 
antigen mimetic. Then, a treatment of 8 with trifluoroacetic acid enabled the 
removal of the Boc protecting group without affecting the silylidene protecting 
group on the galactose moiety, leaving a free amino functionality that under basic 
conditions (triethylamine, NEt3) allowed the intramolecular cyclization to give the 
tricyclic lactam 16 in a 95% yield (calculated over two steps). As a consequence of 
the formation of the lactam ring, the COOBn group is located in the same portion 
of space occupied by the carboxylic group of the Ser or Thr in the native α-Tn 
antigen, confirming the mimetic properties of this tricyclic scaffold.     
 The compound 16 was first treated with a freshly prepared 1M solution of 
tetrabutylamonium hydrogen fluoride (TBAHF) in THF in order to remove the 
sylilidene protecting group [9] and then reacted with acetic anhydride and pyridine 
to form the peracetylated derivative, 17, in 85 % yields over the two steps. The 
final removal of the benzyl ester was performed by palladium catalyzed 
hydrogenation affording the unprotected carboxyl derivative, 4. The free carboxylic 
group will be coupled with the linker 5 which synthesis is described in the 
following paragraph.     
 
 
 
 
 
 
 
 
 
 
 
 
57 
 
3.3 Synthesis of the linker 5 
 The choice of hexaethylene glycol 18 as starting material for the synthesis 
of the linker was dictated by two particular properties: 
 it confers good water solubility to the final product [10]; 
 it ensures an optimal presentation of the α-Tn epitopes towards the external 
environment after the anchorage to the surface of the MNPs. 
 The complete synthesis of the linker monoaminohexaethylenglycol 5 is 
reported in scheme 3.7.   
 
Scheme 3.7 : Scheme of the synthesis of the linker 5.  
 
 Compound 19 was prepared from commercially available hexaethylene 
glycol 18 by reaction with methanesulfonyl chloride (MsCl) using freshly prepared 
Ag2O as a base. This procedure led to the formation of the monomesylate 
derivative as major product, in 48% yield. The azido functional group was inserted 
by reaction of 19 with sodium azide to form 20 in 87% yield [11]. By reducing the 
azide 20 under Staudinger conditions, the product 5 was obtained in 97% yield. 
The so synthesized linker with the free amino group was employed for the coupling 
reaction with 4. 
 
 
 
 
 
 
5 
19 18 20 
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3.4 Synthesis of the α-Tn like derivative 3 : coupling reaction and 
 phosphonate insertion 
 Once the two moieties were prepared, the final step consisted in the 
coupling between the acetylated α-Tn mimetic 4 and the linker 5 followed by the 
insertion of the phosphonate group to obtain the derivative 3, as shown in Scheme 
3.8. 
 
 
 
Scheme 3.8 : Synthesis of phosphonate 3. 
 Compound 4 was reacted with 5 in the presence of O-(benzotriazol-1-yl)-
N,N,N,N'-tetramethyluronium tetrafluoroborate (TBTU) and N-methylmorpholine 
(NMM) to form 21 in 73% yield. By reaction with carbon tetrabromide and 
triphenylphosphine, the terminal hydroxyl group of 21 was replaced with bromine 
to give the compound 22 (88%). The presence of the bromine allowed the 
5 4 
3 
21 
22 23 
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nucleophilic attack of the phosphite in an Arbuzov reaction for the insertion of the 
phosphonate functional group [12]. The bromine derivative 22 was thus heated in 
the presence of tris-trimethyl silyl phosphite (P(OSiMe3)3) affording 23 in 
quantitative yield. The deprotection of acetyl group was performed with a solution 
of ammonia in methanol to give the α-Tn like derivative 3 quantitatively. The so 
synthesized compound 3 presented all the features necessary for our purposes: the 
presence of the Tn-like epitope and the polyoxyethylene chain bearing the 
phosphonate group that will be exploited for the decoration of iron oxide MNPs. 
All the synthetic procedure and characterizations of the product described above 
are reported in the experimental section (Chapter 8). The functionalization of 
MNPs is described in detail in the following paragraph.  
 
3.5 Functionalization of MNPs with the α-Tn antigen mimetic 3 
 The functionalization of magnetite MNPs, IAMNP2, with the α-Tn mimetic 
3 was realized by exploiting the high affinity of the phosphonate group at one end 
of the hexaethylene glycol linker for the iron oxide surface [8]. Thanks to this high 
affinity a complete replacement of the oleic acid by 3 is expected. Indeed, the 
carboxylic group of the oleic acid is weakly bound to the inorganic moiety and the 
formation of covalent linkages with the phosphonate group afford the complete 
replacement of the former surfactant. The establishment of a stable linkage between 
the MNPs and the bioactive ligands is fundamental for biomedical application. In  
fact, the final functionalized MNPs must be stable at physiological conditions and 
also towards other biological entities as enzymes, that could degrade the molecule.  
 The replacement of the surfactants with the mimetic 3 was then 
accomplished by the simple ligand exchange in a chloroform/methanol 10:1 
mixture in order to solubilise the two moieties (the mimetic is soluble in methanol 
but not in chloroform, whereas the MNPs are soluble in chloroform);  then, a 
second exchange process was performed in water in order to increase the 
functionalization rate exploiting the improved water solubility of the MNPs after 
the first ligand exchange process. The final product GMNPs resulted in a stable 
black colloidal water solution.  
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Figure 3.5 : Size distribution by intensity obtained by DLS of GMNPs functionalized with the α-Tn 
mimetic 3. 
 
 DLS measurements (Figure 3.5) revealed the most part of MNPs form 
aggregates, the average size being 182 nm, the polydispersity index = 0.244 and the 
Z-potential was -17.4 mV. However, it must be remarked that the measurements 
were performed after two years. Although after such a long time the most part of 
NPs form aggregates the final product still appeared as a stable colloidal 
suspension.  
 TEM images (Figure 3.6) showed that the inorganic core was unaffected by 
the functionalization process neither in the dimensions nor in the shape, displaying 
MNPs with an almost cubic morphology with a mean size of 10.7±1.2 nm (the 
average size of the oleic acid coated MNPs was 11.3±1.2 nm).  
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Figure 3.6 : Representative bright field low magnification TEM images of MNPs functionalized with the 
α-Tn mimetic antigen. 
 The comparison of the FTIR spectrum of the ligand exchanged product with 
that of  IAMNP2, (Figure 3.7), confirmed the substitution of the oleic acid capping 
agent with the α-Tn mimetic 3: the two sharp bands at 2922 and 2852 cm-1, 
observed in the surfactant coated MNPs and attributed to the asymmetric and 
symmetric CH2 stretching of the aliphatic chains, respectively, disappeared, while 
at lower wavenumber (1120 – 950 cm-1) the modes characteristic of the 
phosphonate group appeared in the spectrum. Of note, the weak band at 990 cm
-1
 
which can be attributed to the ν(P-OFe) mode [13] confirmed that the grafting of 
the mimetic on to the ferrite surface occurred through the phosphonate moiety. The 
characteristic broad envelop at ca. 580 cm
-1
 related to Fe-O bond vibrations was 
detected both in the FTIR spectra, indicating the preservation of the iron oxide core 
after the ligand exchange process.  
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Figure 3.7 : FTIR spectra of the MNPs coated with oleic acid (red line) and after the ligand exchange 
procedure (black). 
 
 The rate of functionalization was estimated on the basis of the phosphorous 
percentage determined via ICP analysis; it was found equal to 2.01∙10-4 mmol/mg 
of MNPs. Assuming an ensemble of identical MNPs with an average size and 
morphology, as indicated by TEM images and the density estimated from the XRD 
pattern, we can assume that on average, each nanoparticle is grafted by 338 α-Tn-
like residues, corresponding to a density of 0.84 molecule/nm
2
, which is 
compatible with an almost complete coating of the iron oxide surface.  
 All together these results confirm the adopted strategy successfully 
provided a stable suspension of MNPs entirely decorated with the a-Tn antigen 
mimetic.   
 
 
 
63 
 
References 
[1] T. Ju; V. I. Otto; R. D. Cummings, Angew. Chem. Int. Ed., 2011, 50, 1770. 
[2] S. Ingale; M. A. Wolfert; J. Gaekwad; T. Buskas; G. J. Boons, Nat. Chem. Biol. 
2007, 10, 663. 
[3] M. A.Hollingsworth; B. J. Swanson, Nature Reviews Cancer, 2004, 4, 45. 
[4] D. M. Coltart; A. K. Royyuru; L. J. Williams; P. W. Glunz; D. Sames; S. D. 
Kuduk; J. B. Schwarz; X.-T. Chen; S. J. Danishefsky; D. H. Live, J. Am. Chem. 
Soc. 2002, 124, 9833. 
[5] (a) F. Venturi; C. Venturi; F. Liguori; M. Cacciarini; M. Montalbano, C.Nativi; 
J. Org. Chem. 2004, 69, 6153; (b) G. Capozzi; R. W. Franck; M. Mattioli; S. 
Menichetti; C. Nativi; G. Valle, J. Org. Chem. 1995, 60, 6416. 
[6] J. Jimenéz-Barbero; E. Dragoni; C. Venturi; F. Nannucci; A. Ardà; M. 
Fontanella; S. André; F. J. Cañada; H.-J. Gabius; C. Nativi, Chemistry Eur. J. 
2009, 15, 10423. 
[7] B. Richichi; B. Thomas; M. Fiore; R. Bosco; H. Qureshi, C. Nativi, O. 
Renaudet and L. BenMohamed, Angew. Chem. Int. Ed., 2014, 53, 11917. 
[8] (a) L. Zhou; J. Yuan;  Y. Wei, J. Mater. Chem., 2011, 21, 2823; (b) T. J. Daou; 
J. M. Grenèche; G. Pourroy;  S. Buathong; A. Derory, C. Ulhaq-Bouillet; B. 
Donnio; D. Guillon; S. Begin-Colin, Chem. Mater., 2008, 20, 5869; (c) Y. Sahoo; 
H. Pizem, T. Fried; D. Golodnitsky; L. Burstein; C. N. Sukenik; G. Markovich, 
Langmuir, 2001, 17, 7907. (d) T. J. Daou; S. Buathong; D. Ung; B. Donnio; G. 
Pourroy; D. Guillon; S. Bégin, Sensor Actuator B, 2007, 126, 159. 
[9] K. Furusawa, Chem. Lett., 1989, 509. 
[10] (a) J. M. Harris Poly(ethyleneglycol) chemistry: biotechnical and biomedical 
applications Plenum Press, 1992; (b) J. H. Lee, H.B. Lee, and J. D. Andrade, Prog. 
Polym. Sci. 1995, 20, 1043. 
[11] F. M. Menger and Hailing Zhang J. Am. Chem. Soc., 2006, 128, 1414. 
[12] (a) A. K. Bhatacharya, Chem. Rev., 1981, 81, 415; (b) L. Lartigue; K. Oumzil; 
Y. Guari; J. Larionova; C. Guérin; J.-L. Montero; V. Barragan-Montero; C. 
64 
 
Sangregorio; A. Caneschi; C. Innocenti;  T. Kalaivani; P. Arosio; A. Lascialfari, 
Org. Lett. 2009, 11, 2992. 
[13] B. C. Barja; M. I. Tejedor-Tejedor; M. A. Anderson, Langmuir 1999, 15, 
2316. 
 
65 
 
4. Synthesis of negative control for biological tests on macrophage 
 activation 
 In Chapter 3 the functionalization of magnetite MNPs with the α-Tn antigen 
(GMNPs) mimetic was described. This nanostructured system was specifically 
designed to act as immunostimulant, which, as will be described in detail in 
Chapter 5, was biologically evaluated through in vitro tests. In order to clearly 
assess the properties of the GMNPs, three diversely functionalized MNPs, to be 
used as negative controls, were prepared. These negative controls are essential to 
quantify the effects induced on cell viability, on cellular uptake and the ability to 
stimulate immune cell response by GMNPs.   
 
 The negative controls prepared were the following: 
 
a) MNPs coated with citrate (CMNPs): they were synthesized in order to 
evaluate the biological effect of MNPs decorated with a non-carbohydratic 
ligand;      
 
b) MNPs coated with methoxy(polyethylenoxy)propyl silane consisting in 9-
12 polyethylene units (PEMNPs): they were prepared to study the effect of 
PEG coating on the cellular uptake. As a matter of fact this polymer is 
known to be "stealth", or rather able to suppress the recognition by the 
immune system through opsonization [1].  
 
c) MNPs coated with a glucose derivative (GlcMNPs): they were employed to 
compare the biological activity of GMNPs, exhibiting the galactosyl 
epitope of the α-Tn antigen mimetic, with MNPs coated with the glucosyl 
epitope that should not stimulate any immune response.  
 
 In Figure 4.1 an outline of the functionalized MNPs prepared as negative 
control is reported. In the following paragraphs we report the synthesis of the 
glucose derivative used for the functionalization of GlcMNPs and we discuss the 
preparation of the three functionalized MNPs samples. 
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Figure 4.1 : Functionalized MNPs prepared as negative controls for biological tests. 
 
4.1 Synthesis of the glucose derivative for MNPs functionalization 
The coating of MNPs with the glucosyl epitope was accomplished by coupling the 
glucose derivative 24 bearing the terminal carboxylic group activated as p-
nitrophenyl ester with the free amino group presents on the MNPs functionalized 
with 3-aminopropyl phosphonic acid (APPA), as outlined in Figure 4.2. Details on 
the synthesis are provided in Chapter 8. 
 
.  
 
Figure 4.2 : Structures of a) the glucose derivative used for the coupling reaction with b) MNPs 
functionalized with 3-aminopropylphosphonic acid (APPA). 
 
a) Citrate coated MNPs (CMNPs) 
b) PEG coated MNPs (PEMNPs) 
c) Glucose coated MNPs 
(GlcMNPs) 
a) Glucose derivative 24 b) MNPs functionalized with 
APPA 
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 Hereafter we describe the synthesis of the glucose derivative 24 including 
the synthesis of products 25 and 26 that will be respectively called "N3-linker" and 
"activated linker", whereas the MNPs functionalization step will be described in 
paragraph 4.2.  
 
          
 
 
 
Scheme 4.1 : Synthesis of a) N3-linker b) activated linker and c) glucose derivative. 
 
 The N3-linker [2] was synthesized in quantitative yield by the reaction of 6-
chloro-1-hexanol, 27, with sodium azide and it was subsequently used in the 
27 25 
N3-linker 
Activated 
linker 
24 
29 26 
31 32 28 
34 33 
30 
a) 
b) 
c) 
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glycosylation of 28 (Scheme 4.1a).The esterification of adipoyl chloride 29 with p-
nitrophenol afforded the activated linker 26 [3] in quantitative yield (Scheme 4.1b) 
and it will be used in the coupling reaction with 30.  
 Concerning the preparation of the carbohydrate moiety the synthesis started 
from the selective deacetylation of the hydroxyl group in position one of β-D-
glucose pentaacetate 31 with hydrazine acetate affording the product 32 in 83% 
yield (Scheme 4.2). 
 
 
Scheme 4.2 : Selective deacetylation of glucose pentaacetate. 
 
 The glycosyl donor 28 was synthesized by a simple base-catalyzed addition 
of the anomeric hydroxyl group of 32 to trichloroacetonitrile giving the α-glucosyl 
trichloroacetimidate selectively and in 74%yield (Scheme 4.3).  
     
 
 
Scheme 4.3 : Synthesis of the α-glucosyl trichloroacetimidate 28. 
 
 Then the glycosylation was accomplished by reacting the glucosyl 
trichloroacetimidate 28 [4] with the N3-linker 25 in the presence of a catalytic 
amount of trimethylsilyl trifluoromethanesulfonate (TMSOTf) as Lewis acid. An 
NMR analysis of the crude product deriving from the glycosylation reaction 
showed the presence of partially deacetylated side products, hence a following 
acetylation with acetic anhydride catalyzed by dimethylaminopyridine (DMAP) 
was performed (Scheme 4.4).     
 
31 32 
32 28 
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Scheme 4.4 : Glycosylation of the glucosyl trichloroacetimidate with the N3-linker. 
  
 The β-glucosyl derivative 33 was obtained in 55% yield, calculated over 
two steps; treatment of 33 with a solution of ammonia in methanol gave a complete 
deacetylation to form 34 in quantitative yield (Scheme 4.5).  
 
 
Scheme 4.5 : Deacetylation of the β-glucosyl derivative. 
 
 
 The azide group of 34 was reduced to amine under Staudinger conditions 
affording 30  (Scheme 4.6) which, in turn, was coupled with the activated linker 26 
by the formation of an amidic bond. 
 
 
 
 
Scheme 4.6 : Azide reduction under Staudinger conditions. 
 
Finally, the glucose derivative 24 with the terminal carboxylic group activated as p-
nitrophenyl ester was obtain in 72% yield over two steps (Scheme 4.7).     
 
 
33 28
  
34 33 
34 30 
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Scheme 4.7 : Coupling reaction between the glucosyl moiety and the activated linker. 
 Compound 24 was then used for the functionalization of MNPs exploiting 
the reactivity of activated ester towards the free amino groups present on the MNPs 
capped with APPA as described in the following paragraph. 
 
4.2 Functionalization of MNPs with citrate, glucose and PEG  
 
 In this paragraph the procedures for the preparation of the previously 
mentioned three MNPs samples employed as negative controls for biological tests 
are discussed in detail. 
 CMNPs were synthesized starting from the same MNPs, IAMNP2, used 
for the functionalization with the α-Tn mimetic by replacing the oleic acid with the 
citrate ligand. The reaction was carried out by reacting MNPs and monohydrated 
citric acid in a 1:1 mixture of 1,2-dichlorobenzene-DMF at 100°C for 24h [5]. The 
resulting CMNPs were soluble in water and no remarkable differences in terms of 
size, size distribution and shape were found, as demonstrated by TEM images; 
indeed, the average size was 11.3±1.2 nm for oleic acid coated IAMNP2 and 
10.9±1.8 nm for citrate coated MNPs (Figure 4.3).  
 
 
Figure 4.3 : TEM images of (A) IAMNP2, MNPs coated with oleic acid and (B) CMNPs coated with 
citrate ligand. Size and shape were retained after the ligand exchange process. 
(A) (B) 
30 24 
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 In Figure 4.4 the FT-IR spectrum is reported. The intense band at 3300 cm
-1
 
was compatible with the presence of non dissociated OH groups of citric acid. The 
peak at 1630 cm
-1
 could be attributed to the symmetric stretching of carboxylic OH 
group; the peak at 1400 cm
-1
 was attributed to the asymmetric stretching of the 
carboxylic CO. Free citric acid has a peak at 1755 cm
-1
 belonging to the carboxylic 
CO vibration and the peak shift observed in this case confirmed the binding of 
citrate to the surface of MNPs.     
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Figure 4.4 : FT-IR spectrum of citrate coated MNPs (CMNPs). 
 
 PEMNPs were prepared by a ligand exchange process starting from oleic 
acid coated MNPs, IAMNP8, synthesized starting from iron(III) acetylacetonate 
[6]. The reaction was accomplished by mixing the nanoparticles with 
methoxy(polyethylenoxy)propyltrimethoxysilane in a 10:1 hexane-chloroform 
mixture in the presence of a catalytic amount of acetic acid. After the ligand 
exchange the MNPs are no longer soluble in hexane but are soluble in ethanol and 
water confirming a modification of the MNP surface occurred. Also in this case no 
significant difference in size and shape was observed from TEM micrographs 
(Figure 4.6). The average size evaluated from a statistical analysis over several 
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micrographs was 12.5±1.6 nm and 12.4±1.8 nm for pristine and PEG coated 
PEMNPS, respectively.  
 The successful functionalization with the PEG-silane ligand was confirmed 
by the FT-IR spectrum of PEMNPs shown in Figure 4.5, where the appearance of 
several peaks in the range of 1430-950 cm
-1
 in which all the CH2-O-CH2 vibrations 
related to the PEG chain occurs. The small band at 1020 cm
-1
 was attributed to the 
Si-O-R stretching whereas the Si-C stretching wad characterized by a peak at 1250 
cm
-1
.      
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Figure 4.5 : FT-IR spectrum of PEG coated MNPs (PEMNPs) 
 
 Finally GlcMNPs were prepared starting from the same MNPs batch, 
IAMNP8, Before the functionalization with the glucose residue the oleic acid was 
replaced with 3-aminopropylphosphonic acid by reacting it with 
tetramethylammonium 3-aminophosphonate salt in a 
hexane/dichloromethane/water emulsion mixed by sonication. The bifunctional 
molecule aminophosphonate was able to anchor the iron oxide surface thanks to the 
phosphonic group while the amino group was exploited for the following coupling 
with the activated carboxylic group of the glucose derivative. The functionalization 
using the tetramethylammonium salt of the phosphonic acid instead of APPA itself 
1020 
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proved to be  more efficient in terms of solubility and stability of the final MNPs 
dispersion.  
 
 
 
Figure 4.6 : TEM image of (a) IAMNP8 coated with oleic acid d = 12.5±1.6 nm (b) PEMNPs coated with 
PEG ligand, d = 12.4±1.8 nm and (c) GlcMNPs functionalized with the modified glucose residue, d = 
12.9±1.5 nm. 
     
 The coupling reaction was carried out by simply mixing the as prepared 
APPA functionalized MNPs with the glucose derivative 24 in DMF thanks to the 
formation of the amide bond between the activated carboxylic group of the 
carbohydrate moiety and the free amino groups present on the surface of the 
nanoparticles. Of note, the same activated glucose derivative 24 was already 
exploited with good results in coupling reactions with free amino groups present on 
ovalbumin with good efficiency (unpublished results). 
  The so synthesized GlcMNPs were purified by magnetic decantation and 
then dispersed in water. The change  in the solubility properties of the MNPs after 
the reaction and the pale yellow coloration of the supernatant due to the hydrolysis 
of the p-nitrophenyl ester were indicative that the coupling occurred.  
 Unfortunately, the IR spectra of GlcMNPs (Figure 4.7) are not very 
informative. Indeed, the most relevant IR peaks of the glucose derivative overlap to 
those belonging to APPA (figure 4.8), which, considering the small number of 
glucose unit loaded, makes extremely difficult to detect the carbohydrate moiety. 
However, the modification of the spectrum occurring in the frequency range 
characteristic for O-H stretching (3500-3200 cm
-1
) together with the variation 
observed in the solubility properties support the formation of the glucose 
functionalized magnetic nanoparticles. 
 
(B) (C) (A) 
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Figure 4.7 : IR spectra of MNPs coated with aminophosphonic acid (APPA) in red and GlcMNPs 
functionalized with the glucose derivative in blue.
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Figure 4.8 : IR spectra in KBr pellet of 3-aminopropylphosphonic acid (red) and glucose derivative 24 
(blue dashed). 
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 Concerning the stability of the GlcMNPs water dispersion, the DLS 
analysis, shown in Figure 4.9 gave an average size of 117 nm with a polydispersity 
index of 0.230, suggesting that the particles formed some aggregates comprising a 
low number magnetic center. Accordingly, a slow sedimentation of the 
nanoparticles was observed over long time. However, the presence of this 
aggregates is not expected to affect in any way the biological test. 
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Figure 4.9 : DLS analysis of samples GlcMNPs  a) size distribution by intensity and b) size distribution 
by number. 
 
 The small peak observed in the micron range was due to some dust 
occurring in the sample which was present in a very small percentage and well 
demonstrated by reporting the weight of each population by number of objects. 
 In conclusion, the ligand exchange with APPA for the subsequent coupling 
with the glucose derivative was successful. However, we still need to improve the 
water solubility and the stability of the aqueous dispersion of the MNPs. To this 
aim, we explored different functionalization methods changing the linker used in 
the ligand exchange reaction, as it will be described in detail in Chapter 6.       
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5. Macrophages activation 
 In Chapter 4 we described the synthesis and the characterization of the 
MNPs functionalized with the α-Tn antigen mimetic (GMNPs) and the MNPs 
prepared as negative controls for biological tests in order to better evaluate the 
effect of GMNPs on immune cells: GlcMNPs (coated with glucose), CMNPs 
(coated with citric acid) and PEMNPs (coated with polyethylene glycol, 9-12 PE 
units). Since macrophages were chosen for the immunoactivity evaluation of our 
samples, in paragraph 5.1 a brief description of the role played by macrophages in 
the immune response is given. In paragraph 5.2 the biological tests, performed on 
MNPs samples mentioned above, are described in detail. 
5.1 Macrophage role in the immune response  
 Macrophages [1] play a critical role in the innate immunity since they 
provide an immediate response against foreign substances representing our first 
line of defence against pathogen agents. They are able to engulf what is recognized 
as non-self in a process called phagocytosis (Figure 5.1).   
 
 
 
Figure 5.1 : Phagocytosis process and phagolysosomes formation. 
 
 When a macrophage ingests a pathogen, the pathogen becomes trapped in 
an intracellular vesicle called phagosome, which then fuses with a lysosome to 
form a phagolysosomes. This process activates various enzymes contained in the 
phagolysosomes, able to produce reactive oxygen species (ROS) and nitric oxide 
(NO) which have a toxic effect towards pathogen agents. Another class of enzymes 
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activated in this process is represented by the lysosomal proteases responsible of 
the degradation of microbial proteins.  
 Besides the ability to engulf and kill microbes, macrophages also help to 
initiate specific defence mechanisms (adaptive immunity) by recruiting and 
activating other immune cells such as lymphocytes through the production of 
cytokines.           
 
 
Figure 5.2 : Interaction between a macrophage and a T lymphocyte. After the phagocytosis process the 
macrophage produces cytokines that activate lymphocytes T CD4
+
. Lymphocytes T CD4
+
 interacts with 
the  macrophage MHC II receptor presenting the antigen and in turn produces IFN-γ that improve the 
macrophage microbial activity.   
 
 Moreover, after digestion of a pathogen, a macrophage will present the 
antigen in association with MHC II receptors to T lymphocytes. 
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  It is worth to note that the antigen is often represented by a fragment of a 
microbic protein and it is used by the immune system for identification. Once a T 
cell has recognized its particular antigen on the surface of the macrophage, the T 
cell becomes an activated effector cell and in turn secretes INF-γ (interferon-γ) that 
improves the macrophage microbicidal activity (Figure 5.2). This cross-interaction 
between macrophages and T lymphocytes is an excellent example of the 
cooperation between the innate immunity and the adaptive immunity, highlighting 
the crucial importance of macrophages activation in the amplification of the 
immune response.           
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5.2 Biological tests 
  
 In the previous paragraph we described the importance of macrophages in 
the immune response, and in this section the biological tests performed are 
described in detail. In particular, our samples were biologically assessed for purity 
evaluating the absence of endotoxin contamination; for biocompatibility, analyzing 
the effects induced on cell viability after 24-72h incubation; for the cellular uptake; 
for immunoactivity, evaluating the ability to stimulate immune cell responses. 
  Before biologically testing, each compound was carefully evaluated 
for purity to rule out the possibility that immune cell responses were due to the 
presence of endotoxin contaminations, such as lypopolysaccharide (LPS), 
introduced into the system through chemicals, materials or equipments. Limulus 
amebocyte lysate (LAL) endochrome assays were, thus, performed in four different 
batches of each compound and the concentration of LPS measured. LPS 
concentrations were always below the value of 0.01 ng/ml, which is  sufficient to 
stimulate immune cell responses [2],
 
suggesting that all compounds under testing 
were LPS-free and biologically evaluable (data not shown). 
 We, then, studied the effects of MNPs on immune cells. For this purpose 
we decided to use macrophages, since they are potent immune cells providing 
immediate responses against dangerous molecules and acting as APCs (Antigen 
Presenting Cells) to stimulate adaptive immune response. Exposure to non-self 
antigens, indeed, can induce a rapid activation of macrophages, which stops 
proliferation and acquires effector cell functions [3]. In the present study a mouse 
monocyte/macrophage quiescent cell line (RAW 264.7) was used, since these cells 
are a widely recognized model of human macrophages [4] with a good 
experimental reproducibility.  
 We analyzed the effects of GMNPs and GlcMNPs on RAW 264.7 cell 
viability in comparison to un-functionalized MNPs, CMNPs, and PEMNPs, 
(controls) and the monovalent α-Tn mimetic 3. We used three validated in vitro 
assays (Trypan blue, calcein-AM, MTT) for toxicity measurements, because it has 
been demonstrated that MNPs can interfere in several of these well-established 
methods, leading to false-negative results [5].
 
Cells were exposed to different 
concentrations (0.01-30 g/ml) of each compound for 24-72 h; thereafter, cell 
viability was measured. No toxicity was determined in any of the three considered 
assays at all the tested concentrations (Figures 5.3), suggesting that all the 
compounds under evaluation are biocompatible. 
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Figure 5.3 : Effects of compound 3, polyethylene glycol-coated MNPs (PEMNPs), citrate-coated MNPs 
(CMNPs), and glycosyl MNPs (GMNPs and GlcMNPs) on cell viability as a function of the 
concentration. RAW 264.7 cells were treated with increasing concentrations (0.01-30 μg/ml) of 3 (closed 
squares), PEMNPs (open triangles), CMNPs (closed circles), GMNPs (closed triangles) or GlcMNPs 
(closed diamonds) for 24h (left panels), 48h (middle panels) and 72h (right panels). A) Cell viability 
assessed by MTT. B) Calcein-AM assay C) Trypan Blue exclusion assay. The concentration-response 
curves show the percentage of cell viability in comparison to controls (compound-untreated cells). The 
data represent mean ± SEM of at least three independent experiments run in triplicate.  
  
 
 
A) 
B) 
C) 
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The next step was to qualitatively investigate by Prussian blue staining the 
cellular uptake of  CMNPs, PEMNPs, GlcMNPs and GMNPs. The typical 
Prussian blue staining images of cells treated with CMNPs (A), GMNPs (B) or 
GlcMNPs (C) showed an intracellular localization of these MNPs, demonstrating 
that both glycosylated (B and C) and not-glycosylated (A) MNPs, can enter into 
macrophages (Figure 5.4). PEMNPs were not endocyted, while the endocytosis of 
the α-Tn antigen mimetic 3, not conjugated to MNPs, cannot be visualized by this 
method.  
 
 
Figure 5.4 : Intracellular MNPs localization. Bright-field images of RAW 264.7 cells treated with 30 
μg/ml of CMNPs (A), GMNPs (B), or GlcMNPs (C) for 24h. MNPs were labelled with Prussian blue 
iron staining and visualized with an optical microscope (objective 40X) equipped with an integrated 
camera. Images are from a representative experiment carried out three times with similar results (scale 
bar = 25 m). 
 
 The endocytosis of 3, CMNPs, PEMNPs, GMNPs and GlcNMPs were 
then quantitatively determined by flow cytometry (FACS). We used side-scattered 
light (SSC) as an indicator of particle uptake: when particles are endocyted by 
cells, SSC intensity increases because the cell granularity is enhanced. Figure 5.5 
shows that the SSC intensity increased after cell treatment with MNPs, either 
functionalized or not, suggesting a similar level of cellular uptake occurs 
independently of the type of carbohydrate attached to the MNP surfaces. In 
contrast, when the cells were exposed to PEMNPs or α-Tn mimetic antigen 3, not 
conjugated to MNPs, the SSC intensity did not change, demonstrating that they 
were not endocyted by macrophages (Figure 5.5). 
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Figure 5.5 : Quantitative evaluation of the 3, PEMNPs, CMNPs, GMNPs, and GlcMNPs uptake. RAW 
264.7 cells were treated with 30 μg/ml of 3, CMNPs, PEMNPs, GMNPs, or GlcMNPs for 24h. The 
compound uptake was determined by measuring the cell granularity by FACS. (A) Representative dot 
plots showing the effects of compound uptake on granularity (SSC) and size (FSC) of RAW 264.7 cells. 
Images are from a representative experiment carried out three times with similar results. (B) Overlay 
plot of the RAW 264.7 cell SSC measured after CMNPs (green), GMNPs (pink), or GlcMNPs (blue) 
uptake. Untreated cells are shade in violet. 
3 
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 By taking into consideration data reported in the literature [6], our results 
can be explained by the peculiar surface properties of the MNPs and, in particular, 
the impact of their charge surface properties on effective phagocytosis. In this 
sense, the citrate-coated MNPs (CMNPs) being negatively charged resulted well 
internalized by macrophages, while the un-charged polyethylene glycol-coated 
MNPs (PEMNPs) were prevented from cellular uptake. Of note, a multivalent 
display of the α-Tn mimetic antigen seems to be necessary for macrophage uptake. 
 Figure 5.6 and  5.7 show the effects of both the concentration and the time 
of cell exposure to each compound on the levels of MNPs uptake, demonstrating 
that the type of coating sensibly influences the kinetic of cellular MNPs uptake.  
 
Figure 5.6 : Time-course of 3, PEMNPs, CMNPs, GMNPs and GlcMNPs uptake. RAW 264.7 cells were 
treated with 30 μg/ml of 3 (closed squares), PEMNPs (open triangles), CMNPs (closed circles), GMNPs 
(closed triangles) or GlcMNPs (closed diamonds) for up to 72 h. At indicated incubation time points, 
cells were harvested and analyzed. The compound uptake was quantified by FACS. The data represent 
mean ± SEM of at least three independent experiments. *p≤ 0.05; **p≤0.01 vs. controls (compound-
untreated cells). 
 
85 
 
 
Figure 5.7 : Concentration-dependence of 3, polyethylene glycol-coated MNPs (PEMNPs), citrate-coated 
MNPs (CMNPs), and glycosyl MNPs (2MNPs and  GlcMNPs) uptake. RAW 264.7 cells were treated 
with increasing concentrations (0.1-30 μg/ml) of 3 (light grey bars), PEMNPs (grey bars), CMNPs 
(hatched bars), GMNPs (dark grey bars) or GlcMNPs (cross-hatched bars), for 24h (A), 48h (B) and 72 
h (C). In each sample, the compound uptake was quantified by FACS. The data represent mean ± SEM 
of at least three independent experiments. *p≤ 0.05; **p≤0.01 vs. controls (untreated cells). 
 Finally, we investigated whether MNPs trigger effector functions in the 
same cells. Figures 5.8 and 5.9 show the effect induced by each compound on the 
production of a typical pro-inflammatory mediator (TNF-α). Remarkably, only the 
MNPs functionalized with the α-Tn mimetic antigen (GMNPs) are able to induce 
TNF- α gene expression and protein release at levels similar to those obtained with 
LPS (0.1 g/ml), while only a 50% of the TNF-α increase was induced by 
GlcMNPs in comparison to GMNPs.  
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 The type of the monosaccharide used in the coating influenced not only the 
levels, but also the time-course of cytokine production: GMNPs determined, 
indeed, a significant time-dependent increase of TNF-α release, while GlcMNPs 
raised a same level of TNF-α releasing, independently of the time considered.  
 
Figure 5.8 : Effects of 3, PEMNPs, CMNPs, GMNPs and GlcMNPs on TNF- gene expression. RAW 
264.7 cells were treated (24h) with increasing concentrations (1-30 μg/ml) of 3, PEMNPs, CMNPs, 
GMNPs or GlcMNPs. Expression of -actin was used as a loading control. Compound untreated cells 
(CTRL) were considered as negative, while 0.1 g/ml LPS-treated cells as positive controls. (A) 
Representative results of RT-PCR for the TNF- and -actin gene expression. (B) The signals were 
densitometrically analyzed and data, calculated as mean ± SEM of at least three independent 
determinations, are expressed as ratio (TNF-/-actin) of the signals obtained for each sample divided 
by that obtained for -actin in the same sample to permit between-sample comparisons. *p≤ 0.05; 
**p≤0.01 vs. controls (compound-untreated cells). 
3 
3 
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Figure 5.9 : Effects of 3, PEMNPs, CMNPs, GMNPs and GlcMNPs treatment on TNF- release. RAW 
264.7 cells were treated with increasing concentrations (0.1-30 μg/ml) of 3 (light grey bars), PEMNPs 
(grey bars), CMNPs (hatched bars), GMNPs (dark grey bars) or GlcMNPs (cross-hatched bars) for 24h 
(A), 48h (B) and 72h (C). Compound untreated cells (white bars) were considered as negative, while 0.1 
g/ml LPS-treated cells (black bars) as positive controls. Supernatants were collected and assayed for 
TNF- levels by standard ELISA. The data represent mean ± SEM of at least three independent 
experiments. *p≤ 0.05; **p≤0.01 vs. controls (compound-untreated cells). 
  
 In agreement with data already published by other authors [7], our results 
showed the biological role played in cellular uptake by the monosaccharide used 
for the MNPs coating. As a matter of fact, it is known [7] that glucose coated 
MNPs are mainly internalized by caveolae-mediated endocytosis, while the 
galactose coated MNPs remain confined on the cell periphery and present a slower 
internalization kinetic. Although the mechanism of GMNPs uptake remains to be 
clarified, taking into account the structural similarity of the α-Tn mimetic antigen 
(decorating GMNPs) and galactose, it is reasonable to suppose that GMNPs may 
follow a cell entrance pattern and processing similar to galactose coated MNPs. 
 Overall, these data demonstrate that a multivalent display of α-Tn mimetic 
antigen is necessary for macrophage activation. Thus, macrophages, after 
processing MNPs as antigenic molecules, become, as discussed in Paragraph 5.1,  
active Antigen Presenting Cells, and through the production of various secondary 
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mediators are capable to orchestrate further cell recruitment for immune responses. 
The macrophages activation is thus a key-point to establish a direct interconnection 
between innate and adaptive immunity and hence for the amplification of the 
immune response, making this novel nanostructured system a good candidate for 
immunotherapy applications. 
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6. Functionalization of MNPs 
 In Chapter 3 we described the functionalization of magnetite MNPs with the 
α-Tn antigen mimetic exploiting a phosphonate group for the anchoring on the iron 
oxide surface. This anchor group was introduced after the coupling of the mimetic 
with the monoamino derivative of the hexaethylene linker, treating the 
carbohydrate moiety with tris(trimethylsilyl) phosphite at a temperature of 100°C 
for 18h. Since, as a future perspective, we aim at extending the proposed approach 
to the functionalization of MNPs with other TACAs (tumour associated 
carbohydrate antigens) and in particular with a mimetic of the GM3 lactone that 
cannot undergo the harsh reaction conditions adopted for the α-Tn antigen mimetic, 
we developed different alternative strategies to anchor it to the inorganic core. 
 
 
 
Figure 6.1 : Structures of the native GM3 ganglioside, its lactone form and the GM3 mimetic with a p-
nitrophenol activated carboxylic group for the conjugation with free amino groups. 
 
 GM3 ganglioside (Figure 6.1) is a TACA overexpressed on melanoma cells 
with metastatic potential [1] and due to its high density [2] and the lower pH of 
tumour cells, undergoes lactonization leading to the formation of the GM3 lactone 
GM3 - Ganglioside 
 
GM3 - Lactone 
GM3 - Mimetic 
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[3]. It has been demonstrated that GM3 lactone is more immunogenic than GM3 
ganglioside [4] but its instability under physiological pH, and thus the decreasing 
of its immunogenicity, led to the development of a stable mimetic of the GM3 
lactone [5]. This mimetic was then modified with a linker bearing an activated 
carboxylic group for the conjugation to the protein carrier keyhole-limpet 
hemocyanin (KLH) able to elicit specific antimelanoma antibodies [6]. Further 
studies on the GM3 mimetic conjugated to complex peptidic structures are 
currently in progress. Since the coupling reaction between this activated carboxylic 
group and a free amino group can occur at room temperature in an aqueous 
medium, the strategy for the functionalization of MNPs was modified as 
schematically represented in Figure 6.2a. In particular, we prepared water soluble 
MNPs with free amino groups exposed to the external environment ready to be 
coupled with a carboxylic group present on the target molecule. These water 
soluble MNPs may be obtained by replacing the former surfactant with a 
bifunctional hydrophilic linker able on one side to bind the inorganic moieties and 
on the other to allow further functionalizations with the bioactive molecule (Figure 
6.2b). 
 In Chapter 4 we have shown that the functionalization of nanoparticles with 
the bifunctional molecule 3-aminophosphonic acid was not completely satisfactory 
because of the non-optimal water solubility of the final product and the formation 
of some aggregates comprising few magnetic centers. In order to improve all of 
these aspects, two diverse bifunctional linkers were studied. In paragraph 6.1 the 
experiments concerning the ligand exchange process of oleic acid coated MNPs 
with an alkoxy silane ligand will be described, whereas the paragraph 6.2 will be 
focused on the synthesis of an amino-phosphonate bifunctional linker derived from 
hexaethyleneglycol.  
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Figure 6.2 : The two strategies followed for the functionalization of MNPs. 
 
6.1 Aminosilane functionalization 
 A ligand bearing a silane anchor group instead of the phosphonate was 
tested in order to improve the stability of the water dispersions and the amount  of 
functionalization. Alkoxysilanes are indeed widely used for the functionalization of 
metal oxide surfaces and in particular for iron oxide nanoparticles as they form 
relatively strong covalent Si-O-Fe bonds.[7] 
 The ligand exchange process was performed on highly uniform spherical 
magnetite MNPs, OlMNP2@290, with average size 17  1.4 nm synthesized by 
thermal decomposition of iron(III) oleate and then oxidized in solution by  
bubbling air following the same procedure described in Chapter 2.2 (Figure 6.3a). 
These MNPs were then reacted with 3-aminopropyltrimethoxy silane (APTMS) 
with catalytic acetic acid [7,8]. Different attempts were performed by varying the 
type of solvent and by carrying on the reaction with or without the presence of the 
surfactant. Performing the reaction in hexane without oleic acid it was not possible 
to obtain an optimal dispersion of the nanoparticles and some aggregates were 
observed. In fact about an hour after the addition of APTMS, the reaction mixture 
became turbid and the nanoparticles tended to stick to the flask walls as an effect of 
the formation of the silane coating. After twenty hours the nanoparticles were 
Oleic acid coated 
MNPs 
Oleic acid coated 
MNPs 
Target molecule with 
phosphonate anchor 
group 
Bifunctional linker 
Functional group 
suitable for further 
coupling with target 
molecules 
Ligand exchange 
Ligand exchange 
(a) 
(b) 
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purified by magnetic decantation and washed to remove the excess of APTMS and 
eventual by-products. The final MNPs were not dispersible in water. Moreover, 
also decreasing the pH to 4-5 by adding a 0.1 M HCl solution in order to protonate 
the amino group present on the ligand so as to promote electrostatic repulsion, did 
not improve the solubility of the suspension. 
 In order to improve the stability of the dispersion of nanoparticles, avoiding 
the formation of aggregates after the ligand exchange process took place, the 
reaction was modified by adding oleic acid just before APTMS. In this case the 
functionalized MNPs resulted more soluble in water after sonication, although  the 
stability was limited to few minutes, also in acidic condition.  
 
 
Figure 6.3 : comparison between (A) oleic acid coated MNPs, OlMNP2@290 used for the 
functionalization with APTMS and (B) the same MNPs after the ligand exchange process in hexane. 
 
 In Figure 6.3 the comparison between the MNPs coated with oleic acid (A) 
and the MNPs after the reaction with APTMS (B) is shown. In the first case the 
nanoparticles were well separated and each one was distinguishable from each 
other. In the case of MNPs functionalized with aminosilane, the formation of 
nanoparticles aggregates embedded in a matrix is clearly observable. In order to 
verify if the MNPs clusters were formed because of the lack of solubility in the 
former hexane dispersion, the reaction was repeated in toluene in the presence of 
oleic acid as surfactant. Using this solvent a more stable dispersion was achieved, 
suggesting a lower degree of aggregation occurred during the ligand exchange. As 
a matter of fact the product obtained after the reaction with APTMS was more 
soluble in water and the dispersion more stable, particularly in acidic conditions, 
although an aggregation process still occurred starting after about one hour. In 
Figure 6.4, a TEM image of the MNPs after the ligand exchange in toluene is 
(A) (B) 
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reported; the image shows  a decrease of the degree of  aggregation and a smaller 
thickness of the organic matrix if compared to the sample prepared in hexane.    
 
 
 
Figure 6.4 : image of MNPs functionalized with aminosilane using toluene as solvent for the ligand 
exchange process. 
 
 In this case the still non-optimal solubility was attributed to an incomplete 
functionalization of the nanoparticles with the aminosilane ligand. Thus, the 
functionalization process with APTMS was repeated twice on the same 
nanoparticles: in the first step a ligand exchange in toluene was performed and in 
the second step the obtained MNPs were redispersed in a 1:1 ethanol/water mixture 
and APTMS was added. At the end of each step the samples were purified by 
dialysis in a cellulose membrane and the process was monitored by elemental 
analysis, before and after purification in order to evaluate the amount of organic 
phase (Table 6.1).  
 
 
 
1
st
 Step 2
nd
 Step 
Solvent Toluene 1:1 EtOH/H2O 
Aminosilane % 
Before   |   After 
8.5%  |   6% 5.0%  |   4.5% 
 
Table 6.1: For each step is displayed the percentage of aminosilane found by elemental analysis before 
and after the purification by dialysis. 
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 As shown in Table 6.1, a decrease of the organic phase during the whole 
two steps process is observed and after the purification of the second step the 
aminosilane percentage decreased from 8.5% to 4.5%, accompanied by a 
worsening of the water solubility. This result led to the conclusion that most of the 
functionalization occurred during the first step and the second reaction in polar 
solvent contributed only in removing the excess of the organic material adsorbed 
on the MNPs. Furthermore, the second addition of APTMS contributed to the 
aggregation by interparticle crosslinking as displayed in Figure 6.5 where a 
representative TEM image of the sample is shown.  
 
 
 
Figure 6.5 : TEM images of the MNPs after the second step of functionalization with APTMS 
 The explanation of the observed behavior is schematized in Figure 6.6: the 
APTMS ligand possesses three hydrolyzable alkoxy  groups and, if on one hand it 
can  form stable Fe-O-Si bonds with the iron oxide surface, on the other it may 
olygomerize forming Si-O-Si bonds with other APTMS molecules [9]. This 
olygomerization will lead to the formation of aggregates of uncontrolled large sizes 
and hence to the formation of unstable water dispersions.  
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Figure 6.6 : Scheme describing APTMS olygomerization and formation of interparticle crosslinking. 
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6.2 Synthesis of aminophosphonic linker 39 
 In order to avoid olygomerization and hence interparticle crosslinking, 
efforts were directed towards the synthesis of a new ligand derived from 
hexaethylene glycol in which each of the two hydroxyl endings were substituted  
by a phosphonate group and an amino group, respectively. Another advantage 
obtained with this linker is the water solubility of the hexaethylene glycol 
derivatives that may increase the total water solubility of the MNPs after the ligand 
exchange. Also the stability of the MNPs dispersions may be positively affected by 
the length of this linker, longer than that of the other investigated ligands; a thicker 
organic shell may decrease dipolar interaction avoiding MNPs aggregation. 
Furthermore, the length of the hexaethylene glycol is necessary to guarantee an 
optimal presentation of the coupled antigen towards the external environments.   
 In Scheme 6.1 the synthesis of the amino-phosphonate linker 39 is reported. 
Details of each step and on the characterization of the intermediates and of the final 
product are given in experimental section. 
    
 
Scheme 6.1 : complete scheme for the synthesis of the amino-phosphonate linker. 
18 19 20 
37 34 
38 39 
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 For the synthesis of compound 20 was followed the same procedure 
described in Paragraph 3.3 [10].  
 The azido derivative 20 was then reacted with carbon tetrabromide and 
triphenylphosphine (PPh3) and the free hydroxyl group was substituted with 
bromine affording 34 in 85% yield (Scheme 6.2). 
 
 
 
Scheme 6.2 : Synthesis of the bromine-azide derivative. 
 
 In order to get the desired ligand we first attempt to substitute the bromine 
with the phosphonate group, 34 by reaction with tris(trimethylsilyl) phosphite 
(P(OSiMe3)3) as reported in Scheme 6.3. 
 
  
Scheme 6.3 : Reaction of the bromine-azide derivative with tris(trimethylsilyl) phosphite did not afford 
the desired product.  
 
 The reaction was monitored by NMR analysis and ESI-MS spectrometry 
highlighting the disappearance of the starting material and the appearance of 
signals belonging to unidentified side products, while no indication on the 
formation of product 35 was found. The reaction scheme was thus modified 
reducing the azide group to amine before the reaction with phosphite. The reaction 
was first performed by reacting the bromine-azide derivative under the Staudinger 
conditions (PPh3 followed by aqueous hydrolysis) as shown in Scheme 6.4.  
 
34 35 
20 34 
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Scheme 6.4 : Attempt to reduce the azide group of 34 to amine under Staudinger conditions. 
 
 The monitoring of the reaction by ESI-MS spectrometry revealed a peak at 
m/z 264 attributed to product 36, indicating that under this conditions the newly 
formed amino group led to the nucleofilic attack to the carbon bound to the 
bromine atom causing the formation of the stable crown ether 36. In order to avoid 
the formation of this cyclic compound the reduction was then performed using H2 
with Pd/C catalyst in the presence of HCl in order to protonate the amino group as 
soon as it is formed, preventing the cyclization reaction (Scheme 6.5). 
 
 
Scheme 6.5 : Successfully reduction of the azide group to amine. 
 
 Following this reaction conditions, the product 37 was obtained in 
quantitative yield. The insertion of the phosphonate group was then attempted 
using 37 as substrate by reaction with P(OSiMe3)3 (Scheme 6.6). The reaction was 
monitored by ESI-MS spectrometry and we observed the progressive 
disappearance of the starting material and the appearance of a peak at m/z 264 
attributed to the compound 36 and others unidentified peaks of side products. 
 
34 36 
34 37 
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Scheme 6.6 : Attempt of phosphonate insertion starting from the bromine-amino derivative. 
 In order to avoid this side reactions caused by the presence of the free 
amino group in the reaction with P(OSiMe3)3, 37 was reacted with di-tert-butyl 
dicarbonate (Boc2O) leading to the Boc-protected compound 38 in 54% yield 
(Scheme 6.7).       
 
Scheme 6.7 : Protection of amino group with di-tert-butyl carbonate.  
 The phosphonate insertion was accomplished by heating  38 in the presence 
of P(OSiMe3)3. The crude product was treated with trifluoroacetic (TFA) acid in 
order to remove the Boc protecting group affording the final product 39 in 
quantitative yield (Scheme 6.8). 
 
 
Scheme 6.8 : Synthesis of the final amino-phosphonate linker. 
 
 In this case the reaction with phosphite did not lead to the formation of 
unwanted side products confirming the goodness of the choice of the amine 
protection with the Boc protecting group. Furthermore, a simple treatment with 
TFA afforded the linker bearing at the two ends a phosphonate and an amino group 
necessary for the anchorage to the iron oxide surface of the MNPs and the 
following coupling reaction with target molecules with an activated carboxylic 
group.   
37 AP10 
37 38 
38 39 
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7. Conclusions and perspectives 
 The aim of this work was to exploit the inorganic core of magnetite MNPs 
as a multivalent scaffold for applications in the therapy of diseases, preserving all 
the advantages offered by their magnetic properties, in addition to those coming 
from the functionalization with bioactive molecules allowing for specific 
interactions with target receptors.   
 In particular, we focused on the development of a nanostructured system 
composed by magnetite MNPs decorated in a multivalent manner with the α-Tn 
antigen mimetic 3, a tumour associated antigen, for application in immunotherapy. 
The synthesis of MNPs was accomplished by the thermal decomposition of 
Fe(acac)3 in a high boiling solvent, exploiting the seed mediated growth process to 
obtain 11 nm MNPs from seeds with a size of 7 nm. The obtained material was 
highly crystalline, with a narrow size distribution and with good magnetic 
properties. The functionalization of MNPs was carried out thanks to the presence of 
the phosphonate group, on the mimetic moiety, which has a great affinity towards 
iron oxide, leading to a stable bond between the galactosyl epitope and MNPs. In 
vitro tests performed on the α-Tn functionalized MNPs revealed their ability to be 
engulfed by macrophages and the ability to activate macrophage effector function, 
inducing gene expression and protein release of TNF-α. Compared to the negative 
controls, only GMNPs was able to induce macrophages  activation, demonstrating 
that a multivalent presentation of the α-Tn epitopes was necessary. The crucial 
importance of these results rely on the role played by macrophages in the immune 
response. The cross-interaction between macrophages and T lymphocytes acts like 
a bridge from the innate immunity and the adaptive immunity making a great 
contribution to the amplification of the immune response. This novel 
nanostructured system is thus proposed as an original immunoactive tool, which 
could find practical applications in immunotherapy as well as for a better 
understanding of the biological properties and clinical applicability of MNPs. Of 
course,  further in vivo studies on GMNPs are needed in order to fully assess their 
immunoactivity and to evaluate their biodistribution by MRI.     
 A further valuable advantage of this nanosystem is undoubtedly provided 
by the presence of an “active” magnetic core, whose properties can be exploited to 
enlarge the number of functionalities and its efficiency. To this aim, and also 
considering the drawbacks which affect the synthetic strategies commonly adopted 
for the preparation of MNPs, large efforts were devoted to the synthesis of 
nanomaterials optimized for magnetic fluid hyperthermia. Different procedures for 
the synthesis of MNPs were thus investigated in order to synthesize larger MNPs 
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(in the 12-15 nm range) in a one step reaction avoiding any seeded process, which 
affect the magnetic properties of the final product. MNPs with this size will 
improve their magnetic and hyperthermic properties without affecting their 
solubility and hence their suitability for further functionalization, essential for 
biomedical application. We found the best experimental conditions, described in 
Paragraph 2.3.2 for sample IAMNP9, were based on using Fe(acac)3 as metal-
organic precursor for thermal decomposition reaction using benzylether as high 
boiling solvent and oleic acid and oleylamine as surfactants. Indeed, these 
parameters, along with a specific heating rate ramp led to MNPs of ca. 14 nm with 
a narrow size distribution, high magnetic moment and a SAR value that could also 
allow for hyperthermic application. We found that this particular size represents the 
best compromise between magnetic/hyperthermic properties and colloidal stability, 
two features which are of fundamental importance for the proposed biomedical 
application. Hence, these MNPs represent the first building block to be employed 
as multivalent scaffold for further functionalization with bioactive molecules, for 
the realization of a novel multifunctional tool for the therapy of tumors.      
 The final part of this work was aimed at developing a more versatile 
strategy towards the functionalization of MNPs compared to that exploited for 
GMNPs: instead of modifying the bioactive molecule to be linked to the MNPs 
moiety, by the insertion of the phosphonate functional group, a more general 
approach was realized by: i) substitution of the former oleic acid surfactant by a 
ligand exchange reaction with a bifunctional linker; ii) coupling of the target 
molecule to MNPs. 
 To this purpose, a new water soluble bifunctional linker derived from 
hexaethylene glycol was synthesized. The linker bears a phosphonate group for the 
anchorage to the MNPs surface at one end, and an amino group for the coupling 
with the target molecule via amide bond, on the other. MNPs functionalized with 
this new linker could be coupled with a series of different molecule depending on 
the final purpose offering a versatile tool for the preparation of targeted MNPs for 
biomedical application. In particular, as a future perspective, our efforts will be 
directed towards the functionalization of MNPs with a mimetic of the GM3 
lactone, a TACA antigen, related to the development of melanoma (see Chapter 6). 
The improvements obtained concerning the synthesis of MNPs with suitable size 
and magnetic properties, and the synthesis of this new bifunctional linker, have 
represented a first fundamental step towards the development of novel 
nanostructured systems for theranostic applications. Indeed, we have now all the 
building blocks to be assembled into a unique system for the desired applications.  
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Moreover, the preliminary in vitro results have shown the potential of MNPs in the 
realization of multifunctional nanosystems and in particular their versatility in a 
new field of application such as immunotherapy.     
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8. Experimental section 
 
Abbreviations  
 
Fe(ole)3: Iron(III) oleate 
Fe(acac)3:   Iron(III) acetyacetonate 
DMF:  dimethylformamide 
APTMS: 3-aminopropyltrimethoxy silane 
Et2O:  diethyl ether 
PE:   petroleum ether 
EtOac:  ethyl acetate 
Ar:  aromatic 
TFA:  trifluoroacetic acid 
NEt3:   triethylamine 
Boc:  tert-butyloxycarbonyl 
TBTU: O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium   
  tetrafluoroborate 
THF:  tetrahydrofurane 
DMAP: dimethyaminopyridine 
PhtNSCl: phthalimidesulfenyl chloride 
DIPEA: N,N-Diisopropylethylamine 
Me:  methyl 
Ac:  acetyl 
Bn:   benzyl 
t-Bu:  tert-butyl 
Boc:  tert-butyloxycarbonyl 
m.p.:  melting point 
rt:   room temperature 
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8.1 Synthesis of MNPs 
 
Synthesis of IOMNP1, IOMNP2, IOMNP3, IOMNP4 
 In a typical thermal decomposition reaction, dried FeOOH fine powder was 
mixed with oleic acid and 1-octadecene in a three neck round bottom flask 
equipped with magnetic stirrer, thermocouple and heating mantle. For IOMNP1 
and IOMNP2 the reaction mixture was purged under nitrogen flow before heating 
and was maintained under a blanket of nitrogen until the end of the heating ramp; 
IOMNP3 was carried out in air atmosphere; for IOMNP4 a flux of air was 
bubbled directly in the reaction mixture since the temperature raised to 180°C. The 
reaction mixture was heated accordingly to the heating rate ramp shown in Figure 
8.1. After the last step at 300°C the reaction mixture was cooled to room 
temperature, diluted with a 2:1 isopropanol-hexane mixture (150 mL), and the 
precipitated material was recovered with a permanent magnet. The obtained 
material was purified by several washing steps with isopropanol and ethanol. In 
Table 8.1 the reagent quantities used in each reaction are reported. 
 
 
    
 
 
 
 
 
 
 
 
 FeOOH Oleic acid  1-octadecene 
 G mmol g mmol V (mL) 
IOMNP1 0.712 8.0 8.950 31.7 25 
IOMNP2 0.364 4.1 6.214 22.0 50 
IOMNP3 0.364 4.1 6. 214 22.0 50 
IOMNP4 0.364 4.1 6. 214 22.0 50 
 
Table 8.1 : Reagents quantities used for each reaction with FeOOH. 
 
Figure 8.1 : Heating rate ramp  for the thermal 
decomposition reactions of FeOOH. 
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Synthesis of Fe(ole)3 
 A solution of FeCl3∙6H2O (2.22 g, 8.23 mmol) and sodium oleate (7.54 g, 
24.8 mmol) in a 1:1.33:2.33 mixture of ethanol-water-hexane, was heated at 70°C 
under magnetic stirring for 4h. The reaction mixture was then washed with water 
(3x6 mL) in a separatory funnel and the organic phase dried with anhydrous 
Na2SO4 and concentrated to dryness to give Fe(ole)3 as a red-brownish waxy solid.  
 
Synthesis of OlMNP1, OlMNP1@290, OlMNP2, OlMNP2@290 
 In a typical thermal decomposition reaction, a solution of  Fe(ole)3 (2.310 g, 
2.6 mmol) and oleic acid (2.440 g, 7.8 mmol), in 1-octadecene (20 mL) was purged 
under nitrogen flow for 15' and then heated according to the heating rate ramp 
reported in Figure 8.2 (tr=4h for OlMNP1 and tr=1.5h for OlMNP2) . The reaction 
mixture was then cooled to room temperature, diluted with isopropanol (100 mL) 
and the precipitated material was recovered with a permanent magnet. The black 
material recovered was purified first by dissolving in hexane and precipitating with 
isopropanol and then by several washing steps with isopropanol and ethanol. The 
obtained OlMNP1 and OlMNP2 were then oxidized by dissolving in 1-octadecene 
(50 mL) and oleic acid (3.00 g, 10.6 mmol) and heating up the reaction mixture to 
290°C for 15' with a flux of air bubbled in the reaction mixture. After cooling to 
room temperature the reaction mixture was diluted with isopropanol (100 mL) and 
the MNPs were recovered with a permanent magnet and washed with isopropanol 
and ethanol giving product OlMNP1@290 and OlMNP2@290. 
 
 
 
Figure 8.2 : Heating rate ramp. tr=4h for OlMNP1 and tr=1.5h for OlMNP2. 
 
Synthesis of IAMNP1 and IAMNP2 
 Magnetite MNPs IAMNP2 were synthesized using a seed-mediated growth 
process based on the Sun’s method [1]. A solution of iron (III) acetylacetonate 
(0.96 g, 2.73 mmol), oleylamine (2.20 g, 8.21 mmol), oleic acid (2.33 g, 8.25 
mmol) and 1,2-hexadecanediol (3.53 g, 13.65 mmol) in 1-octadecene (20 mL) was 
stirred at rt under a nitrogen flow for 1h, then heated to reflux (ca. 320°C) at a rate 
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of 5°C/min and maintained at that temperature for 3h. The mixture was cooled to rt 
and diluted with a 1:1 toluene/heptane solution (10 mL). The mixture was treated 
with a 1:1 ethanol/isopropanol solution and the precipitated material was recovered 
using a permanent magnet. The obtained black powder was washed several times 
with ethanol and then re-dispersed in heptane. This solution was centrifuged at 
2500 rpm for 15 min. Ethanol was added to the supernatant and 7 nm MNPs were 
separated using a permanent magnet and then vacuum dried giving product 
IAMNP1. The obtained IAMNP1 were used as seeds to grow larger MNPs in a 
second thermal decomposition reaction: the MNPs (0.080 g) were mixed with iron 
(III) acetylacetonate (0.601 g, 1.68 mmol), oleylamine (1.92 g, 7.18 mmol), oleic 
acid (1.58 g, 5.59 mmol) and 1,2-hexadecanediol (2.22 g, 8.60 mmol) in 1-
octadecene (20 mL). Larger particles, IAMNP2, were obtained following the same 
procedure described above. 
 
Synthesis of IAMNP3, IAMNP4, IAMNP5, IAMNP6, IAMNP7, IAMNP8 
 In a typical reaction, a solution of Fe(acac)3 (0.354 g, 1.0 mmol), oleic acid 
(1.284 g, 4.5 mmol), oleylamine (0.936 g, 3.5 mmol) in benzylether (50 mL for 
IAMNP3, IAMNP4, and 25 mL for IAMNP5, IAMNP6, IAMNP7, IAMNP8) 
was purged under nitrogen flow for 15' and then heated according to the heating 
rate ramp reported in Figure 8.3a for IAMNP3, IAMNP4 and Figure 8.3b for 
IAMNP5, IAMNP6, IAMNP7, IAMNP8. The reaction mixture was then cooled 
to rt and diluted with ethanol (250 mL). The precipitated material was recovered 
using a permanent magnet and washed several times with ethanol. The black 
powder obtained was then vacuum dried.        
 
 
 
Figure 8.3 : Heating rate ramp a) ti=50',tr=50' for IAMNP3, ti=20',tr=40' for IAMNP4; b) tr=15' for 
IAMNP5, tr=40' for IAMNP6, tr=1.5h for IAMNP7, tr=11' for IAMNP8. 
 
 
a) b) 
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Synthesis of IAMNP9 
 A solution of Fe(acac)3 (0.706 g, 2.0 mmol), oleic acid (2.542 g, 9.0 mmol) 
and oleylamine (1.873 g, 7.0 mmol) in benzylether (30 mL) was purged under 
nitrogen flow for 15' and then heated according to the heating rate ramp reported in 
Figure 8.4. The reaction mixture was then cooled to rt and diluted with ethanol 
(250 mL). The precipitated material was recovered using a permanent magnet and 
washed several times with ethanol. The black powder obtained was then vacuum 
dried. 
 
 
Figure 8.4 : Heating rate ramp exploited for the synthesis of sample IAMNP9.  
 
8.2 Functionalization of MNPS 
 
Synthesis of GMNPs 
 MNPs IAMNP (47.2 mg) were added to a solution of 3 (25 mg, 0.038 
mmol) in 4.4 mL of 10:1 chloroform/methanol, and the mixture was mechanically 
stirred at 48°C for 48h. Methanol was then added to the mixture causing 
precipitation of MNPs. The product was washed with methanol and chloroform in 
order to remove unbound ligand and oleate-coated MNPs and then was vacuum 
dried. The product was dispersed in water by sonication. The solution was 
separated from the precipitate in order to collect only the water soluble MNPs. The 
recovered solution was then freeze-dried leading to a black-brown powder of 
glycosylated MNPs, GMNPs. In order to improve the water solubility of the 
MNPs, 1.5 mg of GMNPs were mixed with phosphonate 3 (1 mg, 0.0015 mmol) in 
mQ water (0.8 mL) and stirred at 45°C for 48h. MNPs were magnetically decanted 
and washed twice with water to remove the unbound ligand. 
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Synthesis of CMNPs 
 In a round bottom flask a 1:1 solution of 1,2-dichlorobenzene/DMF (2.5 
mL) was stirred under a nitrogen flow for 30’, then IAMNP (19.3 mg) and 
monohydrated citric acid (20 mg, 0.05 mmol) were added. The reaction mixture 
was stirred under a blanket of nitrogen at 100°C, for 23h. After cooling at rt, ethyl 
ether was added and the dark-brown material was magnetically decanted. The as 
obtained CMNPs were washed three times with acetone and then vacuum dried. 
 
Synthesis of GlcMNPs 
 To a suspension of IAMNP8 (11.4 mg) in hexane (0.16 mL), an emulsion 
of tetramethyammonium aminopropylphosphonate salt (0.022 g) in a mixture of 
dichloromethane (2 mL) and water (0.05 mL), was added. The reaction mixture 
was sonicated for 30' and then the MNPs were recovered with a permanent magnet 
and washed with isopropanol. To a suspension of the as obtained MNPs in a 1:20 
water/DMF mixture, a solution of 24 in DMF (1 mL) was added. The reaction 
mixture was stirred at rt for 24h and then diluted with a 1:1 isopropanol/hexane 
mixture. The as obtained GlcMNPs were recovered with a permanent magnet, 
washed with ethanol and dispersed in water (1.5 mL). 
 
Synthesis of PEMNPs 
 A toluene solution of IAMNP (2 mL, 10 mg/mL) was diluted in hexane (50 
mL) and mixed with a solution of  
methoxy(polyethylenoxy)propyltrimethoxysilane 9-12 PE units (300 µL) in a 5:1 
hexane/chloroform solution (30 mL). Glacial acetic acid (8 µL, 0.14 mmol) was 
added to the reaction mixture and the solution was stirred at rt for 15h. MNPs were 
separated from the supernatant. The product was washed with chloroform and 
precipitated with hexane with the assistance of a permanent magnet. After the 
washing step the as obtained PEMNPs were dispersed in water (10 mL). 
 
Functionalization with APTMS 
 Here we describe the reaction condition employed for the functionalization 
of MNP with APTMS  discussed in Chapter 6.  
 Experiments were performed: i) in hexane without oleic acid; ii) in hexane 
with oleic acid; iii) in toluene with oleic acid. Typically, 10 mg of OlMNP2@290 
were suspended in hexane or toluene (50 mL). When the reaction was performed in 
the presence of the surfactant, oleic acid (0.025 g) was added to the suspension. 
Then glacial acetic acid (5µL, 0.08 mmol) and APTMS (250 µL, 1.4 mmol) were 
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added. The reaction mixture was stirred for 24h, then the MNPs were recovered 
with a permanent magnet and washed twice with hexane and twice with ethanol. 
 In the case of the further reaction step in water/ethanol: 65 mg of MNPs 
treated with APTMS in toluene with oleic acid, as described above, were dispersed 
in a 1:1 water/ethanol mixture, then glacial acetic acid (85 µL, 1.36 mmol) and 
APTMS (500 µL, 2.8 mmol) were added. The reaction mixture was stirred at rt for 
24h, then the MNPs were recovered with a permanent magnet and washed with 
ethanol. 
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8.3 Synthesis of linker 5 
 
 
 
Monomesylatedhexaethyleneglycol 19 and monoazidehexaethyleneglycol 20 were 
prepared following a reported procedure [2]. Triphenylphosphine (0.480 g, 1.83 
mmol) was added to an ice-cooled solution of 20 (0.271 g, 0.88 mmol) in dry THF 
(2.5 mL). The solution was warmed at 45°C for 2h then H2O (130 μL) was added. 
The reaction mixture was stirred for 15 h at 35°C then diluted with H2O (6 mL) and 
washed with toluene (2 x 4 mL). Evaporation of the aqueous layer under reduced 
pressure gave 5 (0.240 g, 97%) as a pale yellow oil. The spectroscopic and 
analytical data were in agreement with those reported previously [2]. 
1
H NMR (400 MHz, CDCl3) δ: 3.66-3.46 (m, 22H); 2.80 (t, J= 5.1 Hz, 2H) 
13
C NMR (100 MHz, CDCl3) δ: 77.3, 77.0, 76.6, 73.0, 72.8, 70.6, 70.5, 70.4, 70.2, 
70.1, 61.4, 41.5. 
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8.4 Synthesis of α-Tn antigen mimetic 3 
 
Synthesis of 7 
 
 
 
  
To a solution of D-(+)-galactal (1.00 g, 6.88 mmol) in dry DMF (27 mL) cooled to 
-45°C, tert-Bu2Si(OTf)2 (2.5 mL, 7.72 mmol) was slowly added. The solution was 
stirred at -45 °C for 1 h and then anhydrous pyridine (1.50 mL, 18.05 mmol) was 
added. The mixture was warmed to 0°C and a saturated solution of NaHCO3 was 
added until pH=6. The mixture was diluted with Et2O and washed with water (3x25 
mL). The organic layer was dried over Na2SO4, filtered, and the solvent was 
removed under vacuum to give 7 (1.77 g, 90%) as a white solid, and used for the 
following reaction without further purification. The spectroscopic and analytical 
data were in agreement with those reported previously [3].   
p.f. 103-105°C 
1
H NMR (200 MHz, CDCl3) δ: 6.29 (dd, 1H, J1,2= 6.2 Hz, J1,3= 1.4 Hz, H-1); 4.70 
(dt, 1H, J2,1= 6.6 Hz, H-2); 4.41-4.31 (m, 2H, H-3, H-4); 4.24-4.26 (m, 2H, CH2-6); 
3.87 (bs, 1H, H-5); 2.74 (d, 1H, J= 11.4 Hz, OH); 1.07-1.00 (m, 18H, CH3 t-BuSi). 
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Synthesis of 8 
 
 
 
 
 To a solution of 7 (0.50 g, 1.75 mmol) in CHCl3 (2.5 mL), the β-chetoester 
[4] 10 (0.797 g, 2.10 mmol), pyridine (1.7 mL, 21.01 mmol) and PhtNSCl 14 [4] 
(1.16 g, 5.50 mmol) were added. The mixture was heated to 45 °C and stirred for 
16 h, then it was diluted with CH2Cl2 (42 mL) and washed with a saturated solution 
of NH4Cl (3x17 mL). The organic layer was dried over Na2SO4 and the solvent was 
removed under vacuum. After crystallization from Et2O and removal of 
phtalimmide the filtrate was concentrated to dryness and the residue was purified 
by flash chromatography on silica gel (PE/EtOAc 4:1, Rf = 0.53) to afford 8 (0.628 
g, 0.90 mmol, 52%) as a pale yellow solid. The spectroscopic and analytical data 
were in agreement with those reported previously [3]. 
p.f. 85-86°C 
1
H NMR (200 MHz, CDCl3) δ: 7.38-7.30 (m, 5H, Ar); 5.63 (d, 1H, , J1,2=2.8 Hz, 
H-1); 5.39 (bd, 1H, NH); 5.22-5.07 (m, 2H, CH2 Bn); 4.70-4.57 (m, 1H, H-4’); 
4.38 (m, 1H, H-4); 4.31-4.16 (m, 2H, CH2-6); 4.04 (bs, 1H, H-5); 3.74 (s, 3H, 
OCH3); 3.74-3.56 (m, 2H, H-3, H-3’); 3.24 (dd, 1H, J2,1= 3.0 Hz, J2,3= 10.6 Hz, H-
2); 2.86 (B part of an ABX system, 1H, JAB= 14.0 Hz, JBX= 4.4 Hz, HB-3’); 2.65 
(bd, 1H, J= 10.0 Hz, OH); 1.41 (s, 9H, 3 CH3 t-Bu Boc); 1.05 (s, 9H, 3 CH3 t-
BuSi); 1.04 (s, 9H, 3 CH3 t-BuSi). 
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Synthesis of 16 
 
 
 
 
 To a solution of 8 (0.983 g, 1.41 mmol) in dry CH2Cl2 (35 mL), TFA (3.2 
mL, 41.58 mmol) was slowly added at 0 °C. The solution was stirred at rt for 2 h, 
then the mixture was concentrated to dryness. The solid obtained was re-dissolved 
in CHCl3 and NEt3 (3.4 mL, 24.64 mmol) was added. The mixture was heated to 
40°C and stirred for 36h, then it was diluted with CHCl3 (200 mL) and washed 
with water (1x25 mL), with a saturated solution of NH4Cl (2x30 mL) and brine 
(2x30 mL). The organic layer was dried over Na2SO4 and the solvent was removed 
under vacuum to afford 16 (0.753 g, 95% yield over two steps) as a white solid, 
and used for the following reaction without further purification. The spectroscopic 
and analytical data were in agreement with those reported previously [3]. 
m.p.: dec. T>210°C  
1
H NMR (200 MHz, CDCl3) δ: 7.38-7.30 (m, 5H, Ar); 5.97 (bs, 1H, NH); 5.63 (d, 
1H, J1,2= 2.6 Hz, H-1); 5.30-5.22 (m, 2H, CH2 Bn); 4.51 (d, 1H, J4,3= 2.6 Hz, H-4); 
4.35-4.25 (m, 3H, H-5’, CH2-6); 3.99 (bs, 1H, H-5); 3.66-3.74 (m, 1H, H-3); 3.47 
(dd, 1H, J2,1= 2.6 Hz, J2,3= 10.6 Hz, H-2); 2.79 (d, 3H, J= 8.8 Hz, CH2-6’+ bd OH);  
1.07-1.05 (m, 18H, CH3 tBuSi). 
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Synthesis of 17 
 
 
  The glycosylsilylidene 16 (0.753 g, 1.34 mmol) was dissolved into a 
freshly prepared solution of tributylamine hydrofluoride in THF (14.0 mL, 1M). 
The reaction mixture was stirred for 1 h at rt and then concentrated to dryness. The 
residue was dissolved in CH2Cl2 (8 mL) and then pyridine (3.3 mL, 40.2 mmol), 
acetic anhydride (1.27 mL, 13.4 mmol) and 4-dimethylaminopyridine (33 mg, 0.27 
mmol) were added. The reaction mixture was stirred at rt for 10’ and then diluted 
with CH2Cl2 (200 mL) and washed with water (2 x 20 mL), with a 3% solution of 
HCl (2 x 20 mL) and with a saturated solution of Na2CO3 (2 x 20 mL). The organic 
phase was dried over Na2SO4, filtered and concentrated to dryness. The crude was 
purified by flash column chromatography on silica gel (CH2Cl2/Acetone, 7/1) to 
give 17 (0.618 g, 85%) as a white solid. 
m.p.: 173-175°C 
[α]D
25 
= + 89.3 (c 0.75, CHCl3); 
1
H NMR (400 MHz, CDCl3) δ: 7.41-7.32 (m, 5H, Ph), 5.97 (bs, 1H, NH), 5.66 (d, 
J1,2 = 2.8 Hz, 1H, H1), 5.42 (dd, J4,3 = 3.2 Hz, J4,5 = 1.2 Hz, 1H, H4), 5.26-5.23 (A 
part of an AB system, JAB = 12.0 Hz, 1H, CH2Ph), 5.22-5.19 (B part of an AB 
system, JBA = 12.0 Hz, 1H, CH2Ph), 5.06 (dd, J3,2 = 11.6 Hz, J3,4 = 2.8 Hz, 1H, H3), 
4.43 (at, J = 6.8 Hz, 1H, H5), 4.43-4.34 (m, 1H, H5’), 4.14-4.13 (m, 2H, H6a, H6b), 
3.62 (dd, J2,3 = 11.6 Hz, J2,1 = 2.4 Hz, 1H, H2), 2.91-2.85 (A part of an ABX 
system, JAB = 17.6 Hz, JAX = 6.0 Hz, 1H, H4a’), 2.83-2.75 (B part of an ABX system, 
JBA = 16.8 Hz, JBX = 11.2 Hz, 1H, H4b’),  2.16 (s, 3H, COCH3), 2.06 (s, 3H, 
COCH3), 2.02 (s, 3H, COCH3) 
13
C NMR (100 MHz, CDCl3) δ: 170.5 (Cq), 170.1 (Cq), 169.9 (Cq), 169.1 (Cq), 
164.3 (Cq), 154.0 (Cq), 134.7 (Cq), 129.0 (CH, Ph), 128.9 (CH, Ph), 128.6 (CH, 
Ph), 98.2 (Cq), 95.9 (C1), 69.1 (C5), 68.1 (CH2Ph), 67.2 (C4), 65.7 (C3), 61.6 (C6), 
51.5 (C5’), 36.6 (C2), 30.9 (C4’), 20.8 (COCH3), 20.7 (COCH3) 
ESI-MS: m/z 571.84 [M+Na]
+
, 585.83 [M+K]
+
 
Elemental Analysis for C25H27NO11S: calc.  C 54.64, H 4.95, N 2.55; found C 
54.32, H 4.80, N 2. 
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Synthesis of 4 
 
 
 
 
 To a solution of 17 (0.201 g, 0.36 mmol) in THF (14 mL), H2O (0.200 ml) 
and 10% Pd/C (140 mg, 0.04 mmol) were added. The mixture was stirred at rt 
under H2 atmosphere for 2.5 h and then filtered through a pad of Celite®. 
Evaporation of the solvent under vacuum gave 185 mg of crude 4 which was used 
for the following reaction without any further purification. 
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Synthesis of 21 
 
 
 
 
 
 
 To a stirred solution of TBTU (0.234 g, 0.73 mmol) in dry DMF (7 mL), 4-
methylmorpholine (80 μL, 0.73 mmol) was added. The solution was stirred for 20 
minutes at rt, then a solution of 4 (185 mg) in dry DMF (3.6 mL) was added. The 
reaction mixture was stirred for 20’ at rt then a solution of linker 5 (0.100 g, 0.360 
mmol) in dry DMF (1.6 mL) was added. The reaction mixture was stirred for 1h at 
rt then concentrated to dryness. The crude was purified by flash chromatography on 
silica gel (CHCl3/MeOH, 12/1 → 9/1) to give 21 (0.192 g, 73% over two steps) as 
a pale yellow oil.  
[α]D
25
: + 84.3 (c 0.65, CHCl3) 
1
H NMR (400 MHz, CDCl3) δ: 7.56-7.54 (m, 1H, CONHCH2), 6.99 (d, J = 2.8 Hz, 
1H, CONHCH), 5.68 (d, J1,2 = 2.8 Hz, 1H, H1), 5.42 (dd, J4,3 = 3.1 Hz, J4,5 = 1.3 
Hz, 1H, H4), 5.00 (dd, J3,2 = 11.6 Hz, J3,4 = 2.8 Hz, 1H, H3), 4.44 (at, J = 6.8 Hz, 
1H, H5), 4.22 (atd, J = 6.8 Hz, J = 2.4 Hz, 1H, H5’), 4.17-4.00 (m, 2H, H6a, H6b), 
3.74-3.50 (m, 24H, CH2O, H2, H1”), 3.44-3.36 (m, 1H, H1”), 2.99-2.93 (A part of an 
ABX system, JAB = 16.7 Hz, JAX = 7.3 Hz, 1H, H4a’), 2.92-2.86 (B part of an ABX 
system, JBA = 16.7 Hz, JBX = 6.9 Hz, 1H, H4b’), 2.79 (bs, 1H, OH), 2.16 (s, 3H, 
COCH3), 2.06 (s, 3H, COCH3), 2.02 (s, 3H, COCH3) 
13
C NMR (50 MHz, CDCl3) δ: 170.4 (Cq), 170.2 (Cq), 170.0 (Cq), 169.9 (Cq), 
164.3 (Cq), 154.8 (Cq), 97.5 (Cq), 96.0 (C1), 72.9 (CH2O), 70.7 (CH2O), 70.4 
(CH2O), 69.6 (CH2O), 69.1 (C5), 67.4 (C4), 66.2 (C3), 61.8 (C6), 61.7 (C12”), 52.4 
(C5’), 40.0 (C1”), 36.6 (C2), 31.0 (C4’), 20.7 (COCH3) 
ESI-MS: m/z 745.28 [M+Na]
+ 
Elemental Analysis for C30H46N2O16S: calc. C 49.85, H 6.42, N 3.88; found C 
49.79, H 5.68, N 4.22. 
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Synthesis of 22 
 
 
 
 
 To a stirred solution of 21 (0.049 g, 0.068 mmol) in dry CH2Cl2 (2 mL), 
triphenylphosphine (0.025 g, 0.095 mmol) and CBr4 (0.027 g, 0.081 mmol) were 
added. The mixture was stirred at rt overnight then concentrated to dryness. The 
crude was purified by flash chromatography on silica gel (CHCl3/MeOH, 30/1 → 
9/1) to give 22 (47 mg, 88%). 
[α]D
25 
= + 70.1 (c = 0.76, CHCl3) 
1
H NMR (400 MHz, CDCl3) δ: 7.18 (t, J = 5.2 Hz, 1H, CONHCH2), 6.73 (d, 1H, J 
= 2.4 Hz, 1H, CONHCH), 5.69 (d, J1,2 = 2.7 Hz, 1H, H1), 5.43-5.42 (m, 1H, H4), 
5.01 (dd, J3,2 = 11.6 Hz, J3,4 = 3.2 Hz, 1H, H3), 4.44 (at, J = 6.4 Hz, 1H, H5), 4.19-
4.13 (m, 3H, H5’, H6a, H6b), 3.80-3.76 (m, 3H, CH2O), 3.75-3.58 (m, 18H, CH2O, 
H2), 3.49-3.45 (m, 4H, H12”, H1”), 3.00-2.94 (A part of an ABX system, JAB = 16.7 
Hz, JAX = 7.4 Hz, 1H, H4a’), 2.92-2.86 (B part of an ABX system, JBA = 16.7 Hz, JBX 
= 6.8 Hz, 1H, H4b’), 2.16 (s, 3H, COCH3), 2.07 (s, 3H, COCH3), 2.02 (s, 3H, 
COCH3) 
13
C NMR (100 MHz, CDCl3) δ: 170.4 (Cq), 170.0 (Cq), 169.9 (Cq), 164.2 (Cq), 
154.6 (Cq), 97.3 (Cq), 95.7 (C1), 71.1 (CH2O), 70.5 (CH2O), 70.44 (CH2O), 70.41 
(CH2O), 70.39 (CH2O), 70.36 (CH2O), 70.30 (CH2O), 69.4 (CH2O), 68.9 (C5), 67.1 
(C4), 66.0 (C3), 61.5 (C6), 52.2 (C5’), 39.9 (C1”), 36.3 (C2), 30.7 (C4’), 30.4 (C12”), 
20.68 (COCH3), 20.63 (COCH3), 20.5 (COCH3) 
ESI-MS: m/z 785.31 [M+H]
+
, 807.49 [M+Na]
+ 
Elemental Analysis for C30H45BrN2O15S: calc. C 45.86, H 5.77, N 3.57; found C 
46.23, H 5.82, N 3.17. 
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Synthesis of 23 
 
 
 
 
 Compound 22 (0.094 g, 0.12 mmol) was dissolved in tris-
trimethysilylphosphite (1.0 mL, 2.99 mmol) under N2 atmosphere. The reaction 
mixture was warmed at 110°C and stirred for 18h, then concentrated to dryness to 
give 23 (95 mg, quantitative) as a glassy white solid. 
[α]D
25 
= + 77.9 (c  0.28, MeOH) 
1
H NMR (400 MHz, CDCl3) δ: 8.33 (bs, 1H, CONHCH), 7.80 (bs, 1H, 
CONHCH2), 5.70 (d, J1,2 = 2.8 Hz, 1H, H1), 5.41 (bs, 1H, H4), 4.98 (dd, J3,2 = 11.6 
Hz, J3,4 = 3.0 Hz, 1H, H3), 4.44 (at, J = 6.5 Hz, 1H, H5), 4.22-4.13 (m, 3H, H5’, H6a, 
H6b), 3.84-3.46 (m, 25H, CH2O, H2, H1”, H11”, OH, OH), 3.07-3.01 (A part of an 
ABX system, JAB = 16.8 Hz, JAX = 6.0 Hz, 1H, H4a’), 2.98-2.92 (B part of an ABX 
system, JBA = 16.8 Hz, JBX = 7.3 Hz, 1H, H4b’), 2.18-2.10 (m, 2H, H12”), 2.15 (s, 3H, 
COCH3), 2.06 (s, 3H, COCH3), 2.02 (s, 3H, COCH3) 
13
C NMR (50 MHz, CDCl3) δ: 170.4 (Cq), 170.2 (Cq), 169.9 (Cq), 169.8 (Cq), 
165.8 (Cq), 156.1 (Cq), 96.1 (Cq), 95.8 (C1), 70.3 (CH2O), 69.9 (CH2O), 69.7 
(CH2O), 69.3 (CH2O), 68.8 (C5), 67.1 (C4), 65.9 (C3), 65.2 (CH2O), 61.5 (C6), 51.8 
(C5’), 39.7 (C1”), 36.1 (C2), 29.9 (C4’), 27.79 (d, JC-P = 137.2 Hz, C12”), 20.6 
(COCH3) 
31
P NMR (81 MHz, CDCl3) δ: 29.84 (s) 
HRMS: (m/z) calcd for [M+H]
+ 
C30H48O18N2PS 787.23550, found 787.23590. 
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Synthesis of 3 
 
 
 
 
 
 To a stirred solution of 23 (0.095 g, 0.120 mmol) in MeOH (10 mL), a 2.0 
M solution (4 mL) of NH3 in MeOH was added. The reaction mixture was stirred at 
rt for 24h, then concentrated to dryness to give 3 (79 mg) as a white hygroscopic 
solid. Phosphonate 3 was used for the following reaction without any further 
purification. 
1
H NMR (400 MHz, CD3OD) δ: 5.68 (d, J1,2 = 2.8 Hz, 1H, H1), 4.24 (at, J = 6.7 
Hz, 1H, H5’), 4.04 (at, J = 5.9 Hz, 1H, H5), 3.97 (bs, 1H, H4), 3.78-3.71 (m, 4H, 
H6a, H6b, CH2O), 3.65-3.56 (m, 19H, CH2O, H3), 3.47-3.40 (m, 3H, H1”, H2), 2.99-
2.93 (A part of ABX system, JAB = 16.8 Hz, JAX = 6.8 Hz, 1H, H4a’), 2.81-2.75 (B 
part of ABX system, JBA = 16.8 Hz, JBX = 6.8 Hz, 1H, H4b’), 1.95-1.87 (m, 2H, H12”) 
13
C NMR (50 MHz, CD3OD) δ: 172.9, 167.6, 157.9, 98.3, 96.6, 74.9, 71.3, 71.1, 
70.8, 70.3, 70.2, 68.3, 67.1, 62.5, 53.2, 40.5, 40.4, 31.9, 30.84 (d, JC-P = 130.5 Hz);
 
31
P NMR (81 MHz, CDCl3) δ: 20.04 (s) 
HRMS: (m/z) calcd for [M+H]
+ 
C24H42O15N2PS 661.20380, found 661.20272. 
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8.5 Synthesis of glucose derivative 24 
 
Synthesis of 33 
 
 
 
  
 To an ice-cooled solution of 28 [5] (1.173 g, 2.38 mmol)  and 25 [6] (0.452 
g, 3.16 mmol) in CH2Cl2 (12 mL) trimethylsilyl trifluoromethanesulfonate (90 µL, 
0.5 mmol) was added dropwise. The reaction mixture was stirred at 0°C for 1h, 
then neutralized with triethylamine (100 µL, 0.72 mmol), diluted with CH2Cl2 (230 
mL) and washed with a saturated solution of NH4Cl (2 x 10 mL) and brine (1 x 20 
mL). The organic phase was dried over Na2SO4, filtered and concentrated to 
dryness. The crude product (1.55 g) was dissolved in CH2Cl2 (10 mL) and then 
DMAP (0.24 mmol, 30 mg), acetic anhydride (1.13 mL, 11.9 mmol) and pyridine 
(1 mL, 11.9 mmol) were added. The reaction mixture was stirred at rt for 1.5h, then 
diluted with CH2Cl2 (220 mL) and washed with a saturated solution of NH4Cl (3 x 
15 mL). The organic phase was dried over Na2SO4 filtered and concentrated to 
dryness. The crude was purified by flash column chromatography on silica gel 
(petroleum ether/ethyl acetate 3:1) to afford 33 (0.615 g, 55%) as a white sticky 
solid.  
[α]D
25
 = - 11.7 (c 0.31, CHCl3) 
1
H NMR (200 MHz, CDCl3) δ: 5.24-4.93 (m, 3H), 4.48 (d, J = 8.0 Hz, 1H), 4.30-
4.22 (A part of an ABX system, JA,B = 12.3 Hz, JA,X = 4.6 Hz, 1H), 4.16-4.08 (B 
part of an ABX system, JB,A = 12.3 Hz, JB,X = 2.6 Hz, 1H), 3.92-3.81 (m, 1H), 3.72-
3.63 (m, 1H), 3.52-3.41 (m, 1H), 3.25 (t, J = 6.7 Hz, 2H), 2.07-1.99 (m, 12H), 
1.64-1.51 (m, 4H), 1.39-1.31 (m, 4H). 
13
C NMR (50 MHz, CDCl3) δ: 170.7, 170.4, 169.5, 169.3, 100.9, 73.0, 71.9, 71.5, 
70.0, 68.6, 62.1, 51.4, 29.3, 28.9, 26.5, 25.5, 20.8, 20.7.  
Elemental analysis for C20H31N3O10: calc. C 50.73, H 6.60, N 8.87; found C 
50.14, H 6.80, N 9.09. 
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Synthesis of 34 
 
 
 
 
 To a solution of 33 (0.579 g, 1.22 mmol) in CH3OH (2.5 mL), 10 mL of an 
ammonia solution in methanol (2M) was added. The reaction mixture was stirred at 
rt for 18h and then concentrated to dryness. The crude was filtered on a pad of 
silica gel (eluent: ethyl acetate) to give compound 34 (0.365 g, quantitative) as a 
colorless sticky solid.  
[α]D
25
 = - 31.2 (c 0.9, CHCl3);  
1
H NMR (200 MHz, CDCl3) δ: 5.89 (bs, 1H), 5.42 (bs, 1H), 5.15(bs, 1H), 4.67 (bs, 
1H), 4.30 (d, J = 7.5 Hz, 1H), 3.92-3.78 (m, 3H), 3.65-3.47 (m, 3H), 3.39-3.24 (m, 
4H), 1.73-1.53 (m, 4H), 1.46-1.36 (m, 4H). 
13
C NMR (50 MHz, CDCl3) δ: 102.9, 75.7, 73.5, 70.3, 69.5, 61.4, 51.4, 29.5, 28.8, 
26.6, 25.5.  
Elemental Analysis for C12H23N3O6: C 47.20, H 7.59, N 13.76; found C 47.32, H 
7.89, N 13.76. 
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Synthesis of 30 
 
 
 
 
 To a stirred solution of 34 (0.083 g, 0.27 mmol) in a mixture DMF:THF 
(1:10, 5.5 mL) triphenylphosphine (0.147 g, 0.56 mmol) was added. The reaction 
mixture was stirred at 45°C for 35', cooled to rt and then H2O (40 µL, 2.22 mmol) 
was added. The solution was stirred at 45°C for 16h and then concentrated to 
dryness. The crude product 30 was used for the following reaction without any 
further purification. 
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Synthesis of 24 
 
 
 
 
 To a stirred solution of crude 30 (0.240 g) in DMF (0.4 mL), a solution of 
26
 
[7] (0.423 g, 1.09 mmol) in DMF (2.25 mL) was added dropwise. The reaction 
mixture was stirred at rt for 1.5 h then concentrated to dryness. The crude 16 was 
treated with CH3OH and then filtered. The filtrate was concentrated to dryness and 
the crude was purified by flash chromatography on silica gel (CH2Cl2/CH3OH 9/1 
→ 8/1) to give compound 16 in 72% yield over 2 steps as a pale yellow sticky 
solid. 
[α]D
25
 = - 11.2 (c 0.52, CH3OH) 
1
H NMR (200 MHz, CD3OD) δ: 8.32 (d, J = 9.2 Hz, 2H), 7.39 (d, J = 9.2 Hz, 2H), 
4.26 (d, J = 7.9 Hz, 1H), 3.94-3.87 (m, 2H), 3.70-3.67 (m, 1H), 3.57-3.53 (m, 1H), 
3.38-3.25 (m, 3H), 3.22-3.17 (m, 3H), 2.69 (t, J = 7.0 Hz, 2H), 1.93 (t, J = 6.9 Hz, 
2H), 1.83-1.72 (m, 4H), 1.67-1.61 (m, 2H), 1.56-1.51 (m, 2H), 1.46-1.35 (m, 4H). 
13
C NMR (50 MHz, CD3OD) δ: 175.4, 172.4, 156.9, 146.6, 126.0, 123.8, 104.2, 
78.0, 77.8, 75.0, 71.6, 70.6, 62.7, 40.3, 36.6, 34.5, 30.6, 30.3, 27.7, 26.7, 26.3, 25.2. 
HRMS: (m/z) calcd for [M+H]
+
 C24H37N2O11 529.23919, found 529.23949. 
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8.6 Synthesis of amino-phosphonate linker 39 
 
 
Synthesis of 34 
 
 
 
 
 Monomesylatedhexaethyleneglycol 19 and monoazidehexaethyleneglycol 
20 were prepared following a reported procedure [2]. To a solution of 20 (0.128 g, 
0.42 mmol) in anhydrous CH2Cl2 (9 mL), CBr4 (0.167 g, 0.50 mmol) and 
triphenylphosphine (0.155 g, 0.59 mmol) were added. The reaction mixture was 
stirred at rt overnight and then concentrated to dryness. The crude product was 
purified by flash chromatography on silica gel (CH2Cl2/(CH3)2CO 10:1) to give 
product 34 (0.131 g, 85%) as a pale yellow oil. 
1
H NMR (500 MHz, CDCl3) δ: 3.81 (t, J = 6.4 Hz, 2H), 3.69-3.64 (m, 18H), 3.47 
(t, J = 6.4 Hz, 2H), 3.38 (t, J = 5.2 Hz, 2H). 
13
C NMR (125 MHz, CDCl3) δ: 71.3, 70.85, 70.83, 70.81, 70.78, 70.73, 70.6, 50.8, 
30.4. 
ESI-MS: m/z 392.11 [M+Na]
+
, 408.10 [M+K]
+
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Synthesis of 37 
 
 
 
 
 To a solution of 34 (50 mg, 0.13 mmol) in distilled THF (4 mL), an aqueous 
solution of HCl (4.9 M, 55 µL) and 10% Pd/C (58 mg, 0.027 mmol) were added. 
The mixture was stirred at rt under H2 atmosphere for 2 h and then filtered through 
a pad of Celite®. Evaporation of the solvent under vacuum gave product 37 (51 
mg, quantitative) as a green-yellow oil.  
1
H NMR (500 MHz, CD3OD) δ: 3.85-3.79 (m, 2H), 3.77-3.72 (m, 2H), 3.71-3.60 
(m, 16H), 3.57-3.48 (m, 2H), 3.15 (br, 2H).  
13
C NMR (125 MHz, CD3OD) δ: 72.3, 71.4, 71.3, 71.2, 71.1, 70.9, 67.9, 40.7, 
31.5.  
ESI-MS: m/z 344.25 [M+H]
+
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Synthesis of 38 
 
 
 
  
To a solution of 37 (0.103 g, 0.30 mmol),  and di-tert-butyl dicarbonate (0.160 g, 
0.73 mmol) in distilled THF, DIPEA (53 µL, 0.30 mmol) was added. The reaction 
mixture was stirred at rt for 6h and then diluted with CH2Cl2 and washed with brine 
(3x10 mL) and water (3x10 mL). The organic phase was dried over Na2SO4, 
filtered and concentrated to dryness. The crude was purified by flash column 
chromatography on silica gel (CH2Cl2/(CH3)2CO 4:1) to afford 38 (72 mg, 54%) as 
a pale  yellow oil. 
1
H NMR (500 MHz, CDCl3) δ: 3.83 (t, J = 6.4 Hz, 2H), 3.71-3.61 (m, 18H), 3.55 
(t, J = 5.1 Hz, 2H), 3.49 (t, J = 6.4 Hz, 2H), 3.38-3.26 (br, 1H), 1.46 (s, 9H). 
13
C NMR (125 MHz, CDCl3) δ: 156.1, 79.2, 71.5, 71.3, 70.8, 70.7, 70.6, 70.3, 
40.5, 30.4, 28.5.   
ESI-MS: m/z 466.15 [M+Na]
+
, 482.05 [M+K]
+
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Synthesis of 39 
 
 
 
 
 Tris(trimethylsilyl) phosphite (0.9 mL, 2.7 mmol) was added to product 38 
(60 mg, 0.13 mmol), and the reaction mixture was stirred at 100°C, for 48h. The 
mixture was cooled to rt and concentrated to dryness. The colourless oil obtained 
was then dissolved in CH2Cl2 (5 mL) and TFA (210 µL, 27 mmol) was added. The 
solution was stirred at rt for 2h and then concentrated to dryness to afford 39 (62 
mg, quantitative) as a colourless oil.   
1
H NMR (500 MHz, CD3OD) δ: 3.82-3.75 (m, 4H), 3.74-3.64 (m, 16 H), 3.18-3.14 
(m, 2H), 2.12-2.05 (m, 2H). 
13
C NMR (125 MHz, CD3OD) δ: 71.4, 71.3, 71.26, 71.21, 71.1, 70.9, 70.8, 67.9, 
66.7, 40.5, 39.6, 28.5. 
31
P NMR (200 MHz, CD3OD) δ: 24.24 (s) 
HRMS: (m/z) calcd for [M+H]
+
 C12H29NO8P 346.16253, found 346.16154. 
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8.7 Biological tests on macrophages activation 
 Biological tests on macrophages activation were performed in collaboration 
with Prof. G. Lombardi, Dipartimento di Scienze del Farmaco, Università del 
Piemonte Orientale "Amedeo Avogadro". 
 To measure the biological effects of MNPs, either functionalized or not 
functionalized with the -Tn mimetic antigen, the concentration of each compound 
was expressed as g/ml. To allow an easy comparison among compounds the 
correspondence between mass and mole concentrations was also calculated (see 
Table 8.2). 
 
 Compound (g/ml) 
-Tn-epitope 
mimetic (M) 
3 1 1.5 
CMNPs 1  
GMNPs 1 0.2 
 
Table 8.2 : Relationship between mass and mole concentrations of the tested compounds 
 
Cell culture 
  The RAW 264.7 murine macrophage cell line (ATCC TIB-71; American 
Type Culture Collection, Manassas, VA, USA) was cultured in high glucose (4.5 
g/l) Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 2mM L-glutamine, 100 IU/ml penicillin and 
100 μg/ml streptomycin (Lonza, Milan, Italy) and kept in a 37 °C incubator with 
5% CO2. Cells were grown in 75-cm
2
 flasks and sub-cultured by scraping when 
they reached 90% confluence with a 1:5 or 1:10 ratio in fresh medium. Before each 
experiment, viable cell count was assessed by trypan blue staining; thereafter cells 
were seeded and rendered quiescent by 18h serum deprivation. 
 
Limulus amebocyte lysate (LAL) assay 
 LPS levels in each compound were measured in duplicate in serial 1:10 
dilutions of each sample made with pyrogen-free water using a chromogenic LAL 
assay (Lonza, Basel, Switzerland), according to the manufacturer's protocol. The 
sensitivity of the LAL assay was 0.01 ng/ml.  
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MTT assay 
 Cell viability was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyl-tetrazolium bromide (MTT) assay. Briefly, RAW 264.7 cells were seeded 
in 24-well plates and treated with increasing concentrations (0.01-30 μg/ml) of 3, 
PEMNPs, CMNPs, GMNPs or GlcMNPs for 24, 48 and 72 h at 37° C in a 5% 
CO2 humidified incubator. The percentage of cell viability was calculated as (x × 
100)/y, where x, and y were the absorbance read in compound-treated, and 
compound-untreated cells, respectively. 
 
Calcein-AM assay 
 RAW 264.7 cells were labelled with 1 M Calcein-AM (CAM) (Molecular 
Probes, Invitrogen) in serum-free PBS for 15 min at 37° C in the dark. After being 
washed, labelled cells were seeded in 24-well plates and allowed to adhere over-
night at 37° C in a humidified incubator. The day after, RAW 264.7 cells were 
treated with increasing concentrations (0.01-30 μg/ml) of 3, PEMNPs, CMNPs, 
GMNPs or GlcMNPs for 24, 48 and 72 h at 37° C in a 5% CO2 humidified 
incubator. After incubation time the cells of each well were harvested, washed, 
labelled with propidium iodide (PI), and the viability was measured by flow 
cytometry. Lived cells were identified as CAM
high
/PI
-
 population whereas dead 
cells were CAM
low
/PI
+
. Viability was calculated by FACSDiva software and 
expressed as the percentage of CAM
high
/PI
-
 population relative to untreated cells.  
 
Trypan blue-exclusion assay of cell viability 
RAW 264.7 cells were seeded in 24-well plates and treated with increasing 
concentrations (0.01-30 μg/ml) of 3, PEMNPs, CMNPs, GMNPs or GlcMNPs, 
for 24, 48 and 72 h at 37° C in a 5% CO2 humidified incubator. After incubation 
time cells were harvested, stained with a trypan blue solution and counted under an 
inverted microscope. The percentage of cell viability was calculated as (x × 100)/y, 
where x, and y were the number of live and total cells in the same sample, 
respectively. 
 
Qualitative study of MNPs uptake 
 RAW 264.7 cells (5 x 10
4
 cells/well) were allowed to adhere overnight on 
sterile glass cover slips in 24-well culture plates and treated with PEMNPs, 
CMNPs, GMNPs or GlcMNPs (30
 g/ml) in complete medium for 24h at 37°C, 
5% CO2. The cover slips were washed twice with ice-cold PBS to remove unbound 
MNPs and cells were fixed with 4% paraformaldehyde for 15 min at 4° C. After 
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two additional PBS washing, cells on the cover slips were stained with fresh 
prepared Prussian blue reagent (2% potassium ferrocyanide [Sigma Aldrich]/12% 
HCl, 1:1, v/v) for 30 min. The cells were washed five times with PBS, and 
subsequently the cover slips were mounted on glass slides by SlowFade® reagent 
(Invitrogen, Milano, Italy). Cells were then observed by an inverted optical 
microscope (objective x 40) with an integrated camera (Motic AE2000 with 
integrated Moticam 3.0). 
 
Quantitative study of MNPs uptake 
 RAW 264.7 cells were seeded (1 x 10
5
 cells/well) in 12-well culture plates 
and treated with 3, PEMNPs, CMNPs, GMNPs or GlcMNPs (30 g/ml) for 24 h 
at 37° C in a 5% CO2 humidified incubator. Following incubation, cells were 
washed twice with cold PBS to remove unbound MNPs, gently scraped from the 
culture plates on ice, and centrifuged (900 rpm, 5 min, 4°C). Cell pellets were 
resuspended in 200 l PBS containing 2% FBS and analyzed by FACScalibur 
(FACS-Vantage, BD Bioscience, Milan). A total of 5000 viable cells were 
collected for each sample. For calculation cell debris and free particles were 
excluded by an electronical gate containing RAW 264.7 cells of all size and 
granularities in a FSC-SSC-histogram. Univariant histograms of SSC determined 
the mean of cell granularity used as measure of uptake by RAW 264.7 cells. Data 
were analyzed by using FACSDiva software (BD Bioscience, Milan). 
 For uptake time-course determination, RAW 264.7 cells were seeded (1 x 
10
5
 cells/well) in 12-well culture plates and incubated with 3, PEMNPs, CMNPs, 
GMNPs or GlcMNPs (30 g/ml) for up to 72 h at 37° C in a 5% CO2 humidified 
incubator. At different incubation times (1, 3, 6, 18, 24, 48 and 72h) cell samples 
were harvested, prepared and analyzed by FACS, as described above. 
To explore the relationship between cellular uptake and compound concentration 
RAW 264.7 cells were seeded in 12-well culture plates and incubated with 
increasing concentrations (0.1-30 g/ml) of 3, PEMNPs, CMNPs, GMNPs or 
GlcMNPs for 24, 48, and 72 h at 37° C in a 5% CO2 humidified incubator. 
Following incubation cell samples were harvested, prepared and analyzed by 
FACS, as described above.  
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RT-PCR 
 RAW 264.7 cells were seeded (1 x 10
6
 cells/well) in 6-well culture plates 
and treated with increasing concentrations (1-30 μg/ml) of 3, PEMNPs, CMNPs, 
GMNPs or GlcMNPs for 24 h at 37° C in a 5% CO2 humidified incubator. 
Bacterial LPS (0.1 g/ml) -treated and -untreated cells were used as positive and 
standard controls, respectively, for RT-PCR analysis. Total RNA was isolated 
using the GenElute
TM
 mammalian total RNA kit (Sigma Aldrich, Milan) and 
reverse-transcribed to cDNA using ThermoScript RT-PCR
TM
 kit (Invitrogen, 
Milan, Italy), according to the manufacturer’s instructions. For amplification, 3 l 
of cDNA were added to GoTaq FlexiDNA Polymerase (Promega, Milan, Italy) in 
25 l reaction buffer, containing 0.5 M of forward and reverse primers (Table 1S, 
Supplementary Information). Amplification products were resolved in 1% agarose 
gel by electrophoresis and visualized with ethidium bromide. Signals were 
quantified with densitometric analysis software (NIH Image 1.32; Bethesda, MD, 
USA). Data were expressed as the ratio of the signals obtained for each gene in one 
sample divided by that obtained for the reference gene (mouse β-actin) in the same 
sample. 
 
TNF- release 
 RAW 264.7 cells were seeded in 24-well culture plates and treated with 
increasing concentrations (0.1-30 μg/ml) of 3, PEMNPs, CMNPs, GMNPs or 
GlcMNPs for 24, 48 and 72 h at 37° C in a 5% CO2 humidified incubator. 
Bacterial LPS (0.1 g/ml)-treated cells, and -untreated cells were used as positive 
and standard controls, respectively, of TNF- release. At the end of each 
experiment, supernatants were collected and stored at −20 °C until assays. The 
amounts of TNF-α in cell culture media were assayed using enzyme-linked 
immunosorbent assay (ELISA) kits (Biolegend, San Diego, USA), according to the 
manufacturer's instructions. The concentrations of TNF-α in the samples were 
determined by extrapolation from specific reference standard curves. 
 
Statistical analysis 
Results were expressed as means ± SEM of at least three independent experiments 
run in triplicate. Statistical significance was evaluated by the one-way ANOVA 
followed by Student’s t-test for unpaired populations (Graph Pad Software, Inc., 
San Diego, USA). Differences were considered statistically significant when p ≤ 
0.05. 
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8.8 Structural characterization of MNPs 
 
X-ray diffraction (XRD) 
 Powder X-ray diffraction (XRD) measurements were carried out using a 
Bruker D8 Advance diffractometer equipped with Cu Kα (1.54178 Å) radiation and 
operating in θ−2θ Bragg−Brentano geometry at 40 kV and 40 mA. Lattice 
parameters were evaluated on averaging over (400), (511) and (440) peaks. The 
determination of the mean crystallite diameter, d, was performed using the Scherrer 
equation,d = (0.9λ)/(β cosθ), where λ is the wavelength of the incident X-ray 
(1.54178 Å), θ the diffraction angle, and β the full-width at half-maximum. The 
quantification of the phase percentage was obtained analyzing the diffraction 
pattern by the Rietveld method with TOPAS software. 
 
TEM 
 Average diameter and size distribution of the MNPs were determined by 
transmission electron microscopy (TEM), using a CM12 PHILIPS transmission 
electron microscope operating at 100 kV. Samples were prepared by drop drying a 
dilute suspension of MNPs in the proper solvent ( heptane, hexane or water) onto 
200 mesh carbon-coated copper grids. The recorded micrographs were further 
analyzed with the Image Pro-Plus® and ImageJ® software. The mean diameter and 
size distribution of each sample were obtained from a statistical analysis over ca. 
300-700 MNPs depending on the sample. 
 
ICP-AES 
 The determination of Fe, S and P content was performed on a Optima 2000 
Perkin Elmer Inductively Coupled Plasma (ICP) Optical Emission 
Spectrophotometry (OES) Dual Vision. Before analysis, about 1 mg of sample was 
weighted in PE vials and digested on hot plate at 80 °C for 24 hours with 2 mL of 
aqua regia (HCl suprapure grade and HNO3 sub-boiled in 3:1 ratio) and 0.05 mL of 
H2O2 suprapure grade. After the digestion, the samples were diluted to 20 mL with 
ultrapure water (≥18 MΩ). 
 
FT-IR 
 FTIR spectra were collected on a Perkin Elmer Spectrum BX. The sample 
powders were ground with KBr and pressed into a pellet. 
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8.9 Magnetic and hyperthermic characterization 
 
Magnetic Measurements  
 Magnetic measurements were performed using a Quantum Design MPMS 
SQUID magnetometer operating in the 1.8 – 400 K temperature range with a 
magnetic field up to ± 5 T. Measurements on IAMNP2 were performed on a 
dispersion in heptane hosted in a hydrophilic capsule. For the other samples, 
powder MNPs were hosted in a Teflon sample holder and then pressed in a pellet. 
All data were corrected for the diamagnetic contribution of the sample holder and 
of the solvent, which were separately measured. ZFC-FC curves were recorded in 
the 2.5 – 300 K temperature range using a 5 mT probe field. AC susceptibility 
curves were recorded with a 24 A/m field amplitude between 2.5 and 300 K in the 
1 – 1000 Hz frequency range.  
 
Hyperthermic characterization 
 In paragraph 2.2 we described how to evaluate SAR values from 
calorimetric measurements and here is described the experimental setup used in 
this work, that is based on a home-assembled instrument composed of different 
elements (Figure 8.5): 
 A power supply of 6 kW working in the frequency range of 50 – 400 kHz; 
 an induction coil connected to the power supply and cooled with water. The 
working frequency can be selected by selecting the proper combination of 
coil (there are two different coils, made by 2 and 6 windings, respectively)  
and capacitor; 
 a water cooling system; 
 an optical fiber thermometer connected to a digital temperature recorder 
(Fotemp) 
 
 
Figure 8.5 : Power supply MP6-400 6kW®, Fives Celes Inc. and optical fiber thermometer. 
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 Measurements are performed on ca. 400 mL of solution. Typical 
concentrations are in the range 1-10 mg/mL of metal ion. For the temperature 
measurement, the optical fiber is dipped in the sample through a hole in the screw 
cap of the plastic sample holder, which is hosted in a polystyrene support. In order 
to achieve a better thermal isolation from the surroundings and minimize the heat 
exchange the polystyrene holder is placed inside the internal cavity of a 
thermostated system. It is composed by a glass container in which ethylene glycol 
flows, while a thermostat station keeps the desired temperature (Figure 8.6). 
 
 
 
Figure 6 : Ethylene glycol thermostated system. 
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8.10 Characterization of organic compounds 
 
NMR characterization 
 NMR spectra were recorded on a Varian Gemini 200 MHz, on a Varian 
Gemini 300 MHz, on a Varian Inova 400 MHz, on a Varian Mercury 400 MHz, 
and on a Bruker Avance 500 MHz spectrometers. The NMR spectra were 
referenced to solvent. 
 
ESI-MS 
 Mass spectra were recorded on an LCQ-FLEET ion trap Thermo Fischer 
mass spectrometer. ESI-MS analysis was performed both in positive or negative 
ion mode. 
 
Optical rotation 
 Optical rotation measurements were carried out on a Jasco DIP-370 
polarimeter. 
 
Melting point 
Melting points were measured on a Melting point Büchi 510. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
138 
 
References 
[1] S. Sun, H. Zeng, J. Am. Chem. Soc. 2002, 124,  8204. 
 
[2] F. Menger, M. Hailing Zhang, J. Am. Chem. Soc. 2006, 128, 1414. 
 
[3] J. Jimenéz-Barbero, E. Dragoni, C. Venturi, F. Nannucci, A. Ardà, M. 
Fontanella, S. André, F.J. Cañada, H.-J. Gabius, C. Nativi, Chem. Eur. J. 2009, 15, 
10423. 
 
[4] F. Venturi, C. Venturi, F. Liguori, M. Cacciarini, M. Montalbano, C. Nativi, J. 
Org. Chem. 2004, 69, 6153. 
 
[5] R. R. Schmidt, K.-H. Jung, in Preparative Carbohydrate Chemistry Ed. 
S.Hanessian Marcel Dekker, New York, 1997, p.283. 
 
[6] A. Arcangeli, L. Toma, L. Contiero, O. Crociani, L. Legnani, C. Lunghi, E. 
Nesti, G. Moneti, B. Richichi, C. Nativi, Bioconjugate Chem. 2010, 21, 1432. 
 
[7] X. Wu; C.-C. Ling; D. Bundle, Org. Lett., 2004, 6, 4407. 
  
